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Introduction 
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Daily life in a patient with Panic Disorder 
 
Patient A., a thirty-year-old woman, was referred to the Academic Anxiety Center 
(AAC), a tertiary outpatient setting in Maastricht. Since several years, patient A 
experienced panic attacks both at home and outdoors. Palpitations, an 
accelerated heart rate, the feeling of choking and dizziness were the principal 
physical symptoms during the panic attacks. Because these symptoms could be so 
severe, patient A believed she was going to die during a panic attack. Gradually 
she started avoiding situations she perceived as dangerous since getting help, or 
escaping, would not be possible if she would experience a panic attack. 
Convinced that she had a heart disease, she frequently visited the night care, the 
emergency room, the cardiologist and the neurologist but each time she was told 
‘everything was fine’ and that ‘the symptoms were due to stress’. Patient A was also 
a weekly ‘client’ of the general practitioner who now referred her for a diagnostic 
evaluation and, if possible, treatment.  
 
Patient A first received a thorough diagnostic evaluation. The evaluation included a 
history of the present illness and current symptoms, past psychiatric history, review of 
previous treatments, personal and social history including major life events, 
occupational history and a family history with specific attention for anxiety disorders. 
There was also regard for the developmental history and possible stressful events in 
the months before the onset of panic. Next to the full assessment of the features of 
panic disorder and agoraphobia, the presence of other mental conditions was 
evaluated. Before her 25th birthday, patient A had never experienced psychiatric 
com-plaints. Five years ago, however, she experienced her first panic attack in a 
shopping mall. Looking back this was a stressful time as she was just divorced and 
had to take care of her two little children all by herself. Nevertheless, just before the 
panic attack, she was relaxed and enjoining herself with her friends. Patient A was 
brought to the emergency room where an electrocardiogram was performed. After 
he physician reassured her that there was nothing serious going on, he prescribed 
her a benzodiazepine, Oxazepam, and advised her ‘to cut down the stress’. Patient 
A only took one tablet of Oxazepam as she reacted with such an increased feeling 
of lightheadedness, it frightened her even more. The general practitioner next 
prescribed the antidepressant Fluoxetine, an SSRI, but after reading the insert, with 
the instructions for use and a description of possible side effects, she refused to take 
the drug. In the years that followed, she withdrew herself from social activities and 
former hobbies like going shopping and spending time with her friends. Although 
patient A was a devoted runner, she stopped doing exercise, as the acceleration of 
her heart rate due to the physical effort, resembled the symptoms of a panic 
attack. Patient A felt unfitted to accompany her children to the playground or 
swimming pool, which made her feel guilty. She was frequently absent at work what 
even-tually led to her discharge. As a single mother with no support system aside 
from her mother, she had already very limited financial means but they increased 
after she became unemployed. Patient A became more and more social isolated. 
Due to the combination of the panic symptoms, avoidance behavior, social 
isolation and financial problems, she became depressed. Patient A never received 
any psychological treatment. Recently her mother told her that she also has a 
!! ! ! !11!
history of panic attacks, which were successfully treated with cognitive behavioral 
therapy.  
Trying to find an explanation for her panic symptoms, patient A was curious about 
her childhood, but besides separation anxiety at young age in (kinder-garten and 
primary school), there was nothing striking in her development history.  
 
The psychiatric interview included a general medical history and history of sub-
stance use, a review of the patient’s medications, a mental status examination. A 
physical examination was recently done by the general practitioner. Patient A had 
a negative history for medical conditions such as cardiac or respiratory pathology. 
She had also never taken illegal drugs. In spite of the fact that patient A declared 
not to take any medication, she appeared never to leave home without some 
‘over- the- counter’ medication just in case a panic attack would occur. Patient A 
also always carried cookies, a bottle of water and her mobile phone and without 
this ‘safety behavior’ she would never leave her home. Before experiencing the first 
panic attack, patient A smoked cigarettes on a daily basis. After the first panic 
attack, she smoked more cigarettes in an effort to reduce the anxiety (‘as self 
medication’), but after a panic attack occurred during smoking she quitted 
smoking. Patient A did not drink coffee or cola. 
 
To support the diagnosis of panic disorder and (comorbid) depressive disorder, an 
evaluation through the Mini International Neuropsychiatric Interview (MINI) was 
administered. Psychometric evaluation at pretreatment involved the Fear 
Questionnaire (FQA = 25.9), the Panic and Agoraphobia Scale (PAS = 29.7) and the 
Montgomery-Åsberg Depression Rating Scale (MADRS = 21.3). To rule out possible 
general medical causes of panic symptoms like thyroid disease, a blood sample 
was taken. Information about former medication investigation was collected and 
reviewed by the psychiatrist who decided that no additional testing for medical 
causes of panic attacks was needed. As there was no contra- indication, a 35% 
CO2 challenge was administered.  
 
Patient A was diagnosed with panic disorder with (severe) agoraphobia and a 
comorbid (moderate) depressive disorder. From the start, patient A made it very 
clear that she was not prepared to take any medication. The treatment plan 
consistent of psycho-education (4 group sessions) and a 1- week (5 full conse-cutive 
days) in vivo exposure- based behavior therapy program. During this intense week 
patient A devoted her days to exposure to several feared situations. At the 
beginning, the exposure was conducted under full coaching by an experienced 
behavioral therapist, but gradually the coaching was reduced and at the end she 
performed the assignments independently. During the following two weeks, she 
practiced in her home and daily environment. The psychometric evaluation two 
weeks after treatment showed a substantial improvement in panic symptoms, 
avoidance and depressive symptoms (PAS = 7.7, FQA = 8.6, MADRS = 8.1). At that 
time, patient A had already picked up her social activities as well as running and 
she was thinking about applying for a new job. After the session about relapse 
prevention, patient A was discharged.  
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How to diagnose PDA 
 
Panic disorder (PD) is an anxiety disorder characterized by the recurrent occur-
rence of panic attacks and this for more than one month. Panic attacks are spells of 
severe fear or discomfort that have abrupt onset, ‘out of the blue’, without warning 
and for no apparent reason. Even though the duration of a panic attack is short, it 
usually reach a peak within 10 minutes, the symptoms cause much distress. 
 
A panic attack is usually accompanied with a sense of imminent danger, the urge 
to escape and various physical or cognitive symptoms. Physical symptoms can be 
sweating, shaking or trembling, palpitations or accelerated heart rate, sensations of 
shortness of breath or smothering, feeling of choking, chest pain or discomfort, 
abdominal distress or nausea, lightheaded-ness or feeling faint, feeling unsteady or 
dizzy, depersonalization (feeling detached from oneself) or derealization (feelings of 
unreality), paresthesias (numbness of tingling sensations), hot flushes or chills. 
Cognitive symptoms can be the thought of dying, fainting, losing control or going 
crazy. Although PD patients share common features, there can be important 
individual differences in the clinical presentation. Also the frequency of panic 
attacks can vary widely among patients. Since panic attacks are unexpected and 
therefore cannot be predicted, an individual may become anxious or worried 
about the implications of a panic attack or concerned about when the next panic 
attack will occur. The persistent concern is called anticipatory anxiety and is next to 
the panic attacks an essential feature of panic disorder according to the DSM IV 
(APA, 1994).  
 
The concern or worrying about having a new panic attack often leads to significant 
behavioral changes which are intended to prevent panic attacks or cope with a 
panic attack should one occur. Patients start avoiding situations that are perceived 
as dangerous or uncomfortable, often because these situations are associated with 
previous occurrence of panic attacks. The avoidant behavior can gradually 
expand to more and more situations in which having a panic attack would be 
embarrassing or in which escape would be difficult, such as elevators, crowded 
places (restaurants, shopping malls) or driving long distances). The amount of 
avoidance can differ substantially between individuals; from only mild levels of 
avoidance to extreme avoidance. Agoraphobic avoidance can lead to 
considerable dysfunction in several aspects of life and in severe cases even to 
‘homebounding’ in which patients become unable to leave their (‘safe’) home and 
end up being socially isolated and often unemployed. The avoidance behavior is 
referred to as agoraphobia. Although agoraphobia is not a required component of 
panic disorder within the DSM-IV, it is very common in PD (Weissman et al., 1997).  
 
Since panic attacks often occur in other mental and general disorders, panic 
disorder is only in a subset of these individuals the correct diagnosis. To make an 
accurate diagnosis, it is important to determine the context in which the panic 
attacks occur. In many psychiatric disorders (such as specific phobia, social phobia, 
obsessive-compulsive disorder, posttraumatic stress disorder) panic attacks can be 
an associated feature but in contrast with PD, the panic attacks in these disorders 
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are triggered by a specific external stimulus, whereas in PD, the panic attacks are 
seen as from bodily internal origin. Caffeine (and related compounds in beverages), 
medications (stimulants, decongestants, agents to treat asthma, over-the-counter 
medications) and drugs (‘intoxication with or withdrawal from’) can also provoke or 
exacerbate symptoms of a panic attack. Therefore, only if panic attacks do not 
occur solely as a result of another mental disorder, general medical condition or 
(intoxication or withdrawal from) drugs, a concomitant diagnosis of panic disorder 
may be warranted.  
 
The use of explicit diagnostic criteria and structured interviews has greatly improved 
diagnostic reliability of PD, basis for its syndromal validity, for the information we 
obtain from the PD patients about their symptoms, is subjective and entirely 
retrospective. To be able to study the PD symptoms better, models of panic were 
developed using different types of challenges to provoke panic under laboratory 
conditions. We call these models ‘challenges’ because they intentionally put the 
subject under strain by either manipulating of a physiological parameter or 
administration of a pharmacological agent. The parameter or agent that is used in 
order to get more insight in the underlying pathophysiology of panic disorder is 
believed to be directly related to the pathogenesis of panic disorder. Based on the 
criteria proposed by Guttmacher et al. (1983) inhalation of a vital capacity of 35% 
CO2 can be considered a good experimental model (Uhde and Tancer 1990 based 
on Guttmacher et al. 1983 and Gorman et al. 1987).  
 
What does it mean for the individual and for society 
 
Panic disorder is a common and often disabling mental disorder. The twelve month 
prevalence of PD is estimated around 1% and the lifetime prevalence rates ranges 
from 1,5 to 4,7 % (Mendolowiz and Stein, 2000; Norton et al., 2008; Pane – Farre et al., 
2014). It is important to note that about 22,7% of people of the general population, 
experience a (isolated) panic attack once in their lifetime without this leading to the 
development of a panic disorder (Kessler et al. 2006). The gender and the age of 
onset of the panic disorder in-patient A, are typical in PD; the mean onset in panic 
disorder is 25 years and women are more at risk (about twofold) for developing PD 
(Kessler et al., 2006). The onset in women can range from 25 to 35 years and in men 
from 30 to 45 years (Wittchen and Essau, 1993,). Panic disorder has a high degree of 
comorbidity with other anxiety disorders like social phobia (20-75%), generalized 
anxiety disorder (20%), obsessive-compulsive disorder (14%) and post- traumatic 
stress disorder (6%) (Goisman et al., 1994; Overbeek et al., 2000; Pelissolo and Lepine, 
1998). Also depression is a frequent comorbid complication of PD with lifetime 
comorbidity of up to 60% (Weissman et al., 1997). PD can have a great impact on 
several parts of daily life including social relationships, work, school, family, leisure 
activities and therefore cause much suffering (Katerndahl and Realini, 1997; Kessler 
and Frank, 1997). 
 
Since PD is associated with multiple physical symptoms, many PD patients are 
convinced that they have a heart or lung disease, it is highly prevalent in primary 
care, occurring in 4-6% of patients. Because of the intense symptoms that 
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accompany panic disorder, several symptoms closely resemble a life-threatening 
physical illness such a myocardial infarction or acute asthma, patients visit 
frequently emergency rooms where they often receive extensive and extremely 
costly medical check-ups to rule out ‘severe somatic’ pathology. The fact that the 
treating physician has decided that these tests are necessary in combination with 
not receiving a conclusive explanation for their complaints, creates further anxiety 
and leads to ‘medical shopping’ and hence high health costs (Katon et al., 2002; 
Zaubler and Katon, 1998).  
 
Factors that have an influence 
 
In an effort to avoid panic attacks, to reduce the (anticipatory) anxiety and to be 
able ‘to go out’, patients with PD develop all kinds of behavior, hoping that this 
behavior can help them to achieve these goals. Like in the story of patient A, after 
experiencing an attack many PD patients start using benzodiazepines, start smoking 
more, start carrying medication/ bottles/ food if they have to leave their home, stop 
doing exercise. Smoking, however, seems to exacerbate rather than reduce panic 
symptoms. Comorbidity, like a concurrent depressive disorder, may also influence 
the severity of the panic symptoms. Next to these environmental factors, we cannot 
rule out the role of genetics in PD. Since the mother of patient A had panic attacks 
in the past, patient A has a positive familial psychiatric history, which is not 
uncommon in PD patients.  
 
Common safety behaviors  
 
Common safety behavior is behavior that provides the patient with an imme-diate 
feeling of safety and security, especially if the patient leaves his or her ‘safe’ home. 
This behavior includes carrying food, bottles, medication (prescribed or ‘over the 
counter’), mobile cell phone but also ‘carrying’ somebody along so they never 
leave their home alone. Safety behavior also includes determining exit routes and 
checking locations of hospitals for example when they go on a holiday (Kamphuis 
and Telch, 1998). It is important to explore before treatment the extent of this safety 
behavior since it can disguise the degree of avoidance and it prevents obtaining 
the maximum benefit from exposure in vivo (Salkovskis et al., 1999).  
 
Benzodiazepines 
 
Research shows that patients with panic disorder have higher than average 
percentages of sedative abuse and dependence (Anthony et al., 1989; Conway et 
al., 2006; Kushner et al., 1990; Mirin et al., 1991; Nunes et al., 1988; Sareen et al., 
2006). Although some patients experience anxiolytic effects using benzodiazepines 
(Bolton et al., 2006), sedatives can worsen panic symptoms since dizziness or 
lightheadedness, known side effects of sedatives, can resemble the symptoms 
accompanying a panic attack. In spite of the potential side effects of 
benzodiazepines, an advantage of benzodiazepines is their more rapid therapeutic 
response compared to antidepressants (Goddard et al., 2001; Pollack et al., 2003; 
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Woods et al., 1992). Their early onset of action can be useful for patients who 
experience very distressing symptoms and in whom a fast reductions of the panic 
symptoms is necessary, for instance to start CBT or in anticipation of the effect of an 
antidepressant. Since there is much evidence about the difficulty to diminish the 
dose of the benzodiazepine, the advantages and disadvantages of 
benzodiazepines should be carefully considered since ongoing use will lead to 
psychological dependence in most PD patients. There is no solid evidence in the 
literature to support the general idea that long-term use of benzodiazepines leads 
to gradually higher dosages (APA, 1990; Nagy et al., 1989; Pollack et al., 1993; 
Soumerai et al., 2003). However, the lack of studies following longer periods of 
benzodiazepine use especially in PD patients makes it difficult to draw definite 
conclusions about benzodiazepine tolerance. There is however no discussion in the 
literature about the clear risk of withdrawal symptoms and relapse into panic 
symptoms during the discontinuation of benzodiazepines, so caution is necessary 
(Ballenger et al., 1993; Pecknold and Swinson, 1986; Schweizer et al., 1990). 
Alprazolam (Ballenger et al., 1988; Chouinard et al., 1982; Curtis et al., 1993; Dager 
et al., 1992; Dunner et al., 1986; Tesar et al., 1991; Schweizer et al., 1993; Sheenan et 
al., 1984) and clonazepam (Moroz and Rosenbaum, 1999; Tesar et al., 1991; 
Valenca et al., 2003) have shown their efficacy in the treatment of PD, but 
diazepam and lorazepam, when given in equivalent doses, may be as effective 
(albeit at a cost of stronger sedative effects). 
 
Exercise 
 
Patient A stopped doing exercise because the acceleration of her heart rate, due 
to the physical exercise, resembled a panic attack. Since there are more and more 
data suggesting that aerobic exercise benefits patients with a depressive or anxiety 
disorder, exercise is also recommended in the treatment of anxiety disorders 
especially with a concurrent depression (Broman- Fulks et al., 2004; Stathopoulou et 
al., 2006;Strohle et al., 2005). Even though studies showing the positive effect of 
aerobic exercise on panic symptoms in PD are still scarce, the psychiatrist should 
nevertheless consider incorporating aerobic exercise (e.g., walking for 60 minutes or 
running for 20–30 minutes at least 4 days per week) in the treatment plan of PD 
patients since this can also be used as a form of interoceptive exposure (Esquivel et 
al., 2008;Stein et al., 1992).  
 
Smoking cigarettes 
 
Patient A already smoked cigarettes before the first panic attack, briefly smoked 
more cigarettes after experiencing the first panic attack in an attempt to control her 
anxiety and the panic attacks (‘self-medication’) but decided to quit smoking after 
experiencing a panic attack during smoking. Although all these ‘steps’ have been 
described in previous literature in an effort to elucidate the temporal pattern of the 
relationship between smoking and panic, the literature has given inconclusive 
results. There is no discussion however about the unequal proportion of PD patients 
that smoke cigarettes compared to patients with other anxiety disorders and to 
healthy people. Since the respiratory system plays a key role in maintaining the 
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partial pressure of carbon dioxide (pCO2), O2 and the pH within a narrow 
physiological range in the body, CO2 is a considered a basic factor in the control of 
breathing. The fact that the 35% CO2- challenge elicits the same type of panic- like 
symptoms with prominent respiratory symptomatology (such as breathlessness), as 
well in healthy subjects as in patients, suggests a link between respiration and panic 
attacks (Colasanti et al., 2008). This is in line with epidemiologic research that shows 
that the prevalence of panic disorder in COPD patients is notably increased 
compared to the general population (Livermore et al., 2008; Mikkelsen et al., 2004). 
Although the temporal pattern is still under debate, there is literature suggesting that 
daily smoking increases the risk for panic attacks and panic disorder. Since quitting 
smoking has also many benefits for the general health, smoking cessation 
interventions should be considered in any case if the PD patient is a smoker. Since 
there is evidence supporting the idea that smoking can be anxiogenic but also 
anxiolytic (Goodwin et al., 2005; Isensee et al., 2003), the question remains if 
‘smoking leads to panic’ or ‘panic leads to smoking’.  
 
Genetics 
 
Although there is growing interest in defining the genetic basis for PD, and research 
has led to increasing knowledge on PD and genetics, there is still not enough 
evidence to reach a clear conclusion about the role and extent of genetic 
influence in the etiology of PD. However, studies comparing the phenotype 
prevalence among unaffected controls’ relatives with that of affected probands’ 
relatives clearly showed that PD aggregates in some families (Goldstein et al., 1994; 
Goldstein et al., 1997; Horwath et al., 1995; Maier et al, 1993; Mendlewicz et al., 1993; 
Noyes et al., 1986). Several studies also show that healthy first- degree relatives of PD 
patients have an elevated CO2 reactivity that is intermediate between healthy 
controls without a familial PD history and PD patients, suggesting an association 
between genetics and CO2 hypersensitivity (Coryell, 1997; van Beek and Griez, 
2000). The study of Schruers et al. (2011) suggests that the 5-HT transporter gene 
moderates the dose- dependent fear reaction to CO2 administration since 
individuals with the LL genotype showed a stronger fear reaction to CO2. The meta-
analysis of Hettema et al (2001) showed an estimated heritability of 30%-40%, 
suggesting that the environment also contributes significantly to PD’s pathogenesis. 
To date, the extent of the contribution of genetics versus environmental factors on 
PD is still not clearly defined.  
 
Comorbidity 
 
Research has clearly shown the large extent of comorbidity associated with panic 
disorder (Alonso et al., 2004; Bijl and Ravelli, 2000; Klerman et al., 1991; Sanderson 
and Andrews, 2002). Among PD patients, the life- time prevalence of major 
depression is estimated 34.7% and if agoraphobia is associated, the lifetime 
prevalence estimation is 38.7% (Kessler et al., 2006). It has been suggested that 
approximately one-third of the PD patients are depressed when they present for 
treatment of the panic symptoms (Lesser et al., 1989). If there is an associated 
depressive disorder present, the PD patient is at risk for greater impairment, more 
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hospitalizations, and generally more psychopathologi-cal symptoms (Bowen et al., 
1994; Roy-Byrne et al., 2000). The issues concerning treatment of the PD patient with 
a concurrent depressive disorder, will be addressed elsewhere in this chapter.  
 
Treating panic disorder 
 
In the Dutch guidelines for treating panic disorder, the choice for a ‘stepped care 
model’ has been made. Patients with severe panic disorder and (severe) 
agoraphobia have, in addition to psychoeducation, two options; cognitive 
behavioral therapy (CBT) versus pharmacotherapy. In case of an associated 
depressive disorder, adding an antidepressant from the start of treatment is advised. 
Patient A however refused to take medication. To avoid problems in the therapeutic 
alliance and taken into account that she wasn’t severely depressed, we respected 
her decision but we came to the agreement to assess the depressive symptoms at 
regular intervals, as becoming more depressed could interfere with the 
psychological therapy focusing on PD. If patient A had chosen to take medication 
instead of CBT, an SSRI (selective serotonin reuptake inhibitor) would have been 
prescribed. According to the guidelines the pharmacological steps in treating PD 
are (first) SSRIs, (second) TCAs (tricyclic antidepressant), (third) benzodiazepines and 
(fourth) a MAO (monoamine oxidase) inhibitor. Since PD patients easily mis-interpret 
physical sensations, they can be sensitive to side effects and therefore it is 
recommended to start with a low dose. The extent of avoidance seems to be a 
stronger predictor of functional impairment and quality of life than the frequency of 
panic attacks (Telch et al., 1995). Therefore, the aim of the treatment of PD is not 
only to decrease the frequency and intensity of panic attacks but also to reduce 
the anticipatory anxiety and the agoraphobic avoidance. Before treatment, it is 
crucial to establish the extent of the avoidance since the treatment is intended to 
minimize impairment in daily life and so to improve the quality of life. At the same 
time, there should be regard for the presence of ‘safety- behavior’ since it often 
masks the extent of the avoidance behavior.  
 
An extensive body of evidence has documented the efficacy of CBT for the 
treatment of panic disorder (Barlow et al., 1989; Beck et al., 1992; Black et al., 1993; 
Clark et al., 1994; Craske et al., 1991; Craske et al., 1997; Craske et al., 2003; Kenardy 
et al., 2003; Klosko et al., 1990; Ost et al., 1995; Ost et al., 2004; Telch et al., 1993) and 
the effects are robust and durable (Butler et al., 2006; Clum et al., 1993; Gould et al., 
1995, Mitte 2005; Westen and Morrison, 2001). Exposure in vivo is an essentail 
component of CBT. Several studies have examined the use of exposure in vivo, also 
called situational exposure, specifically for patients with panic disorder who also 
have a significant form of agoraphobia (van den Hout et al., 1994; Ito et al., 2001; 
Marks et al., 1993; Ost et al., 1993; Shear et al., 1994). Based on the current literature, 
CBT is the first choice in the treatment for panic disorder and exposure in vivo is 
indicated if agoraphobia is present. Exposure in vivo involves encouraging and 
confronting patients to expose themselves to a wide range of situations that 
normally provoke fear. Although there is evidence for a small advantage for the 
combination treatment (pharmacotherapy and CBT) versus CBT alone in the acute 
phase of the treat-ment, combined therapy seems not to have beneficial effect in 
the long run (but there is evidence that combination therapy is superior to 
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pharmacotherapy alone) (Furukawa et al., 2006). In practice, combination therapy 
is often used to assist in the resolution of severe panic symptoms at the beginning of 
the treatment.  
 
If there is a co-occuring depressive disorder present, treating the depressive disorder 
should be an additional goal since the depression may affect the treatment and 
prognosis of panic disorder (Bowen et al., 1994; Roy- Byrne et al., 2000). If depressive 
symptoms are so severe that they interfere with the treatment for panic disorder, for 
example if the depressed patient has no energy to perform the exposure 
assignments, the depression becomes the primary focus of treatment. With regard 
to CBT, some evidence suggests that CBT focusing on the panic disorder, may also 
improve the depressive symptoms (Brown et al.,1995; Tsao et al., 1995; Tsao et al. 
2005) but in these studies severe depressed patients were always excluded. 
 
Many studies show that 12 weekly sessions of CBT, called short-term CBT, are 
effective in treating PD (Barlow et al., 2000; Brown and Barlow, 1995; Craske et al., 
1991; Fava et al., 1995; Fava et al.; 2001). In an effort to make CBT available to more 
patients, and the urge to think about cost-effectiveness of treatments, there have 
been attempts to give CBT in a more high-density format. Results from these studies 
suggest that this format can be effective (Deacon and Abramowitz, 2006; Hahlweg 
et al., 2001).  
 
Although a full remission of symptoms and return to a premorbid level of functioning 
should be the ultimate goal at the start of the treatment, some patients continue to 
have limited panic attacks or recurrent episodes of panic symptoms even if the 
treatment was perceived as successful (Bruce et al., 2005; Katschnig et al., 1996; 
Roy- Byrne and Cowley, 1995). Studies show that at 4–6 years post-treatment, about 
30% of patients treated in a tertiary-care setting are well. Of the remaining 70 %, 
40%–50% are improved but symptomatic and 20%–30% have symptoms that are the 
same or slightly worse (Katschnig et al., 1996; Roy- Byrne and Cowley, 1995). Before 
discharge, a personalized relapse prevention plan should be developed so the 
patient knows how to act if panic symptoms should recur.  
 
In line with the guidelines patient A had psycho-education, CBT and a session of 
relapse prevention. In contrast with the guidelines, she didn’t receive at least 12 
weeks of CBT and she didn’t take an antidepressant to treat her depression. 
However, according to both the post- treatment assessment and our clinical 
observations, panic and depressive symptoms were diminished to such an extent 
that patient A didn’t fit the criteria of panic disorder or depressive disorder anymore.  
Two questions remain, however; is a 12-week CBT program necessary to treat PD 
successfully or can this be intensified? In case of a comorbid depression, is adding 
and antidepressant necessary to treat the depression?  
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What do we need to improve the life of the PD patient? 
 
Although relapse after remission is more frequent than maintained remission and 
improvement with lingering symptoms is more the rule than remission, treatment of 
PD can be effective and can improve quality of life of the individual substantially. 
Untreated PD can become a chronic and severe invalidating anxiety disorder with 
high economic costs for society. To date, the exact underlying pathophysiology of 
panic remains largely unknown, yet is clear that the development of the clinical 
presentation of PD depends on an interaction between genetic and environmental 
factors. More insight in the genetic determinants of susceptibility of panic, together 
with more knowledge on, and the identification of, the environmental factors of PD, 
can pave the way for new therapeutic approaches.  
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This thesis regards environmental and genetic factors in panic disorder (PD). 
Consecutively, we have studied the impact of environmental factors such as 
smoking and cognitive behavioral therapy (CBT) on panic disorder. Finally, we 
studied the influence of the 5-HTTLPR genotype on CBT focusing on avoidance 
behavior in panic disorder. With CO2 inhalations as a model to provoke panic and 
smoking as a technique to enhance this panic provocation, our first aim was to 
establish and explain the panic effects of smoking. Since the cause and temporal 
pattern of this comor-bidity remains controversial, we then reviewed previous 
literature on this topic. Next, we investigated the effect of cognitive behavioral 
therapy (CBT), with exposure in-vivo as the main technique, focusing on 
avoidance/agoraphobia in panic disorder patients. First we investigated the effect 
of intensified ‘one week’ CBT versus classical ‘two-weekly’ sessions. Next, we studied 
the effect of comorbid depression on therapy focusing on PD in depressed versus 
non-depressed PD patients. In these studies CBT is considered the environmental 
factor since we modulated the environment what lead to changes in the 
symptomatology of panic disorder. Finally, we examined the effect of the 5-HTTLPR 
genotype on CBT focusing on agoraphobia in PD patients with severe agoraphobia. 
 
A disproportionately large number of persons with panic disorder smoke cigarettes 
compared to people in the general population and individuals with other anxiety 
disorders. Since clinical and epidemiological data suggest that cigarette smoking 
increases the risk for the development and maintenance of PD, it was hypothesized 
in chapter 1 that cigarette smoking facilitates the emergence of CO2-induced 
panic (‘from smoking to panic’). To test this hypothesis the 35% carbon dioxide 
(CO2) challenge was used to experimentally induce symptoms compatible with a 
panic attack. It was expected that smokers would respond stronger to the 35% CO2 
challenge when compared to non-smokers. Ninety-two subjects (46 smokers and 46 
non-smokers) with PD participated in the study. Several explanations for the link 
between smoking and panic disorder were also discussed. 
  
Given that the link between smoking and panic disorder remains controversial and 
that the temporal pattern of this relationship is still a matter of debate in 
epidemiological studies, in chapter 2 the literature was searched in order to 
determine the validity of the proposed explanatory models. The aim of the study, 24 
studies were reviewed, was also to achieve a broader perspective on the link 
between panic and cigarette smoking and to identify the possible underlying 
etiologic mechanisms.  
 
In chapter 3 the efficacy of a brief, intensive, clinician-guided exposure program for 
panic disorder patients with severe agoraphobia was described and compared to 
a more classical form of behavioral therapy involving twice-weekly contacts with a 
therapist. The main outcome parameter was the agoraphobia score of the Fear 
Questionnaire (FQ-AGO). The outcomes of 96 patients after a 1-week intensive 
therapy and 98 patients after a twice-weekly therapy were compared. 
 
The fact that cognitive behavioral therapy (CBT) is a highly effective form of 
treatment for panic disorder with agoraphobia (PDA) is well established. Panic 
disorder and depression are highly comorbid, however, and studies examining 
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treatment outcome for panic disorder with comorbid depression have produced 
mixed results. In chapter 4, the following hypotheses were tested; (1) a comorbid 
depressive disorder in PD patients results in is more severe PDA symptoms at 
baseline; (2) patients with and without comorbid depression improve to a 
comparable degree; (3) behavioral therapy for PDA result also in a clinically 
relevant reduction in depressive symptomatology as measured with the MADRS. Six-
hundred-and-eighty-nine patients were included in the study. Out of 421 patients 
who entered manualized behavioral therapy, 288 completed the post-treatment 
assessment. One third of these 288 patients were depressed (N = 87). Those who 
completed the post-treatment assessment were analyzed categorically as well as 
dimensionally regarding the influence of depression by dividing into 2 groups 
(comorbid depressive disorder or not) and 3 groups (according to their MADRS- 
score) respectively. These groups were then compared regarding their PDA and 
depression outcomes at baseline and post-treatment.  
 
The serotonin transporter length polymorphism (5 HTTLPR) is one of the most widely 
researched genotypes in affective neurosciences and has received much attention 
over the last years in the study of gene-environment (GxE) interactions. Important 
efforts are invested in elucidating the genetic factors that can predict the effects of 
pharmacological therapy for psychiatric disorders. Also relevant but much less 
researched is the influence of genotype on the efficacy of psychological therapy. 
To identify biological markers for individualization of cognitive behavior therapy is of 
both of theoretical and clinical interest. To date, there are very few studies 
investigating the role of genetic variants in the efficacy of CBT in panic disorder and 
agoraphobia. Chapter 5 reports on the findings of the study that was intended to 
assess the extent to which the low-expression allele of the serotonin transporter gene 
promoter predicts a better response to exposure-based behavior therapy in patients 
with PDA. Ninety-nine patients with PDA underwent a 1-week in-vivo exposure-
based behavior therapy program and were classified according to four allelic forms 
(SA, SG, LA, LG) of the 5-HTT-linked polymorphic region (5-HTTLPR) genotype. 
Whether the 5-HTTLPR genotype predicted change in avoidance behavior in PDA 
following treatment was determined, using the Fear Questionnaire as main outcome 
measure. It was hypothesized that the S-allele would be associated with enhanced 
response to therapy. 
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Abstract 
 
Background 
A disproportionately large number of persons with panic disorder (PD) smoke 
cigarettes compared to people in the general popula-tion and individuals with 
other anxiety disorders. Clinical and epidemiological data suggest that cigarette 
smoking increases the risk for the development and maintenance of PD. The carbon 
dioxide (CO2) challenge is well established as experimental model for panic. The 
present study seeks to examine whether cigarette smoking has an influence on 
laboratory elicited panic in PD patients. 
 
Methods 
In total 92 subjects (46 smokers and 46 non-smokers) with PD, according to the DSM-
IV criteria, were compared. All subjects received a baseline clinical assessment and 
underwent a 35% CO2 challenge. Response to the challenge was evaluated via the 
Panic Symptom List and the Visual Analogue Fear Scale. 
 
Results 
The two samples did not differ on baseline anxiety level. Smokers had a significantly 
higher increase in panic symptoms in response to the challenge compared to non-
smokers (p = 0.04). Limitations: This type of study does not provide information 
concerning the underlying mechanisms of the link between smoking and panic. 
Study limitations include lack of formal assessment of personality and of inter-rater 
reliability. 
 
Conclusions 
The present findings are consistent with the idea that smoking facilitates panic in PD 
subjects. This may have clinical implications, as quitting smoking could become one 
of the relevant steps in the treatment of PD patients. 
 
Key words : Smoking, Panic Disorder, Carbon dioxide, Challenge 
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1. Introduction 
 
A disproportionate number of people with panic disorder (PD) smoke cigarettes 
compared to those in the general population and to individuals with other anxiety 
disorders (Breslau et al.,1991; Amering et al., 1999; Johnson et al., 2000). Panic has 
been strongly associated with occasional smoking, regular smoking and nicotine 
dependence (Isensee et al., 2003; Breslau et al., 2004) according to a bidirectional 
pattern of association going from smoking to panic and from panic to smoking 
(Isensee et al., 2003). 
Clinical and epidemiological data suggest that cigarette smoking increases the risk 
of developing certain anxiety disorders, in particular PD (Morissette et al., 2006). 
Longitudinal studies, in both adults and adolescents, have shown that daily smoking 
is related to an increased risk of initial occurrence of panic attacks (PAs) and PD 
(Breslau and Klein, 1999; Johnson et al., 2000). 
Several explanations have been proposed for this relationship. 
The first hypothesis posits an anxiogenic effect of nicotinecon-sumption and 
conceptualizes smoking as a risk factor for panic (‘from smoking to panic’) (Klein, 
1993; Breslau and Klein, 1999; Pine et al., 2000; Caldirola et al., 2004; Zvolensky et al., 
2004; Esquivel et al., in press). 
The second hypothesis implies an anxiolytic effect of nicotine (‘from panic to 
smoking’) (Pohl et al., 1992; Kassel and Shiffman, 1997). 
Finally, a shared vulnerability (genetic or environmental) may also explain this co-
occurrence (Goodwin and Hamilton, 2002). 
The majority of these studies however have been conducted in naturalistic settings, 
allowing no conclusion regarding the direction of this relationship. Laboratory based 
tests can be a useful additional research step in this respect. 
In recent years, experimental psychiatry has developed different paradigms to 
provoke panic in an experimental setting. Experimental studies using laboratory 
panic provocation procedures focus on the underlying mechanisms of the 
panic/smoking link. The 35% CO2 inhalation method has proven to be a specific, 
valid, reliable, and safe way to induce experimental panic (Griez and Schruers, 
1998; Esquivel et al., in press). 
Previous experimental studies using the voluntary hyperventilation pro-cedure 
(Zvolensky et al., 2004) and the 4- minute 5% CO2 rebreathing challenge (Abrams et 
al., 2008) have shown that smokers react more on measures of fear, anxiety or 
distress. Cosci et al. (2006) however, comparing healthy smoking and non-smoking 
volunteers, found no difference on the response to the 35% CO2 challenge. 
Considering the heterogeneity of methods in experimental studies and the fact that 
the temporal pattern, in epidemiological studies, is still a matter of debate, we 
designed a study to examine whether cigarette smoking has an influence on 
laboratory elicited panic in panic disor-der patients. We administered 35% CO2 
challenge to regular smokers with PD and compared them to non-smokers with PD. 
We hypothesize that cigarette smoking facilitates the emergence of panic (‘from 
smoking to panic’) and therefore expect smokers to respond stronger to the 35% 
CO2 challenge compared to PD non-smokers. 
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2. Methods 
 
2.1. Subjects 
The sample consisted of 92 outpatients with panic disorder; 46 smokers and 46 non-
smokers (22 men in each group). 
Participants were recruited from our outpatient setting. All participants were 
screened by an experienced psychiatrist. They had a medical history inventory, a 
psychiatric evaluation to confirm the diagnosis according to the DSM-IV criteria 
(APA, 1994) and an evaluation through the Mini International Neuropsychiatric 
Interview (Sheehan et al., 1994) to support the diagnoses. 
Only patients with PD as primary diagnosis were included. Exclusion criteria: 
cardiovascular/ pulmonary disease, significant hypertension, pregnancy, epilepsy, 
cerebral aneurysm, use of concurrent psycho-tropic medication and adrenergic 
receptor blockers. None of the patients had been on diazepam or fluoxetine that 
requires a longer wash-out period. Patients with concurrent psychiatric disorders, 
according to the DSM- IV criteria (APA, 1994) were not excluded: in the smokers 
group one patient had a social phobia, one patient had a somatoform disorder, 
one patient had a dysthymic disorder and three had major depressive disorder. 
In the non-smokers group there was one patient with generalized anxiety disorder, 
two with social phobia, one with somatoform disorder and three with major 
depressive disorder. 
No formal assessment of personality was made. 
The study was approved by the local medical ethics committee and all patients 
gave their informed consent after a detailed explanation of the entire procedure. 
 
2.2. Procedures 
All patients had a complete medical history and a psychiatric evaluation performed 
by an experienced psychiatrist. They were evaluated about smoking habits. Age of 
onset of smoking was defined as the age at which they started to smoke daily for at 
least 4 weeks (Breslau and Klein, 1999; Isensee et al., 2003). The amount of cigarettes 
smoked daily was also assessed. Current smokers had to use tobacco on daily basis 
for a period of at least 4 weeks continuously 
(Breslau and Klein, 1999; Isensee et al., 2003). Non-smokers were defined as those 
who never used tobacco products. 
Before the 35% CO2 inhalation procedure, clinical assessment of anxiety was 
performed by using three scales. The State–Trait Anxiety Inventory—State version 
(STAI-S) is a self-administered scale to assess momentary anxiety (Spiel- berger et al., 
1970). The State–Trait Anxiety Inventory—Trait version (STAI-T) is a self-administered 
scale to assess general anxiety (Spielberger et al., 1970). The Fear Questionnaire (FQ) 
is a self-rating scale which assesses agoraphobia, blood-injury phobia and social 
phobia. It produces a global score (FQ-tot) and subscores for agoraphobia (FQ-
AGO), blood-injury phobia (FQ-BI) and social phobia (FQ-SOC) (Marks and 
Mathews, 1979). 
Before and after the 35% CO2 inhalation, physiological and psychological 
symptoms were assessed using a Visual Analogue Scale of Fear (VAS-F) and the 
Panic Symptom List (PSL) which have been regularly used to assess experimental 
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anxiety (Perna et al., 1995; Schruers et al., 2000). The procedure of the 35% CO2 
challenge has been described elsewhere (Schruers and Griez, 2004). An increase in 
at least four physical symptoms of the PSL together with an increase of at least 25 
units in the VAS-F were used as criteria for an experimental panic attack. 
 
2.3. Data analysis 
Chi square test was used for categorical variables (gender, occurrence of CO2 
challenge induced panic attack). For non- categorical data with a normal 
distribution Student's t-test was used (age, FQ Total, FQ-AGO, STAI-S, STAI-T, VAS-F, 
PSL). The results are presented as means ± standard deviations and significance 
levels were set at p < 0.05 (two-tailed). The main outcome measures were the delta 
VAS-F and delta PSL. Deltas are calculated as 35% CO2 post-challenge minus 35% 
CO2 pre- challenge scores. 
 
3. Results 
 
Ninety-two patients (46 smokers and 46 non-smokers) with a diagnosis of panic 
disorder were evaluated (Agoraphobia was diagnosed in about 76% of the 
patients). There was no significant difference between both groups concerning 
gender (24 of the smokers and 24 of the non-smokers were female) or age (33.9 ± 
10.6 in smokers and 35.7 ± 12 in non-smokers; p = 0.46). 
Among smokers, the mean daily consumption of cigarettes was 14.8 ± 8.9 (n = 42). 
Fifty percent (n =23) smoked 1–10 cigarettes per day, 39% (n = 18) smoked 11–20 
cigarettes per day, 6% (n =3) smoked 21–30 cigarettes per day and 4% (n =2) 
smoked more than 30 cigarettes per day. 
The two samples did not differ regarding avoidance behavior or level of anxiety as 
evaluated at baseline by means of the FQ Total, FQ-AGO, STAI-S and STAI-T (Table 
1). Smokers and non-smokers did also not significantly differ for VAS-F and PSL pre-
challenge scores (Pre-VAS-F: 25.3 ± 21.3 in smokers and 28.6 ± 24.5 in non-smokers; p 
=0.49. Pre-PSL: 4.1 ± 4.6 in smokers and 4.6 ± 4.3 in non-smokers; p =0.55), for VAS-F 
and PSL post-challenge scores (Post-VAS-F: 69.1 ± 22.3 in smokers and 65.2 ± 24.8 in 
non-smokers; p =0.4. Post-PSL: 17 ± 9.2 in smokers and 14.3 ± 7.3 in non-smokers; p = 
0.12) or for delta VAS-F (43.8 ± 23.8 in smokers and 36.3 ± 23.6 in non-smokers; p = 
0.13). However, smokers had lower VAS-F and PSL scores immediately before the 
challenge and reached higher scores immediately after (Figs. 1 and 2). The delta 
PSL scores revealed a significant difference between the smokers and non-smokers 
with smokers displaying a stronger reaction (12.9 ± 8.3 in smokers and 9.7 ± 6.7 in 
non-smokers; p = 0.04). Finally, smokers and non-smokers did not differ as for number 
of 35% CO2 induced panic attacks. 65% (30/46) of smokers versus 56% (26/46) of 
non-smokers (p = 0.39). 
 
4. Discussion 
 
The present study shows that PD smokers responded stronger to a 35% CO2 panic 
challenge compared to PD non-smokers. PD smokers reacted with more panic 
symptoms to the challenge while baseline measures were similar in both groups. 
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Fear scores showed the same effect, however without reaching statistical 
significance as has been the case in previous studies (Cosci et al., 2004, 2005). The 
findings fit the hypothesis that prior regular smoking increases the risk for panic 
attacks in PD patients. 
 
Table1. Comparison of PD smokers and PD non-smokers on clinical characteristics 
and severity of panic disorder as assesses at baseline 
 Smokers  Non-smokers  p 
 N Mean SD N Mean SD  
STAI-S 42 45.3 13.0 42 46.4 13.3 0.69 
STAI-T 18 47.4 13.6 16 44.0 11.6 0.45 
FQ Total 41 39.1 23.2 40 37.0 25.3 0.70 
FQ-AGO 41 15.2 11.8 41 12.6 13.2 0.35 
Student's t-test for independent samples. 
 
 
 
Fig. 1. Comparison of PD smokers with PD non-smokers concerning pre- and post-
challenge assessment with PSL. Student's t-test for independent samples. ⁎p < 0.05, 
two-tailed. Error bars: +/−2 SE. 
 
A previous study in our laboratory was aimed at testing whether nicotine has a 
direct influence on laboratory-elicited panic (Cosci et al., 2006). We compared 
healthy non-smokers undergoing a 35% CO2 challenge after a transdermal admin 
istration of a nicotine or placebo patch, according to a cross- over design. Nicotine 
did not significantly affect the reaction to the 35% CO2 challenge compared to 
placebo. At first sight, these previous results don't seem to agree with the present 
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study. Yet, lack of response to the 35% CO2 challenge itself, may have several 
explanations. 
 
 
 
Fig. 2. Comparison of PD smokers with PD non-smokers concerning pre- and post-
challenge assessment with VAS-F. Students t-test for independent samples. Error 
bars : +/- 2 SE. 
 
First of all, in the previous study nicotine was administered acutely, while in the 
present study cigarette smoking was used as a proxy of chronic exposure to 
nicotine. In real life, smokers are also chronically or sub-acutely exposed to nicotine 
and this may imply a different pharmacological effect (De Graaf et al.,2002; Isensee 
et al., 2003). It is conceivable that a longer exposure to nicotine is more likely to 
cause increased sensitivity to the challenge, as demonstrated in the present study. 
Second, the previous study was carried out in healthy volunteers, not in PD patients. 
Recent results from our group showed that while a single 35% CO2 inhalation is 
capable of provoking panic in PD patients, this stimulus is not sufficiently strong in 
most healthy volunteers (Griez et al., 2007). 
Third, in the previous study nicotine was administered via nicotine patches. It can be 
argued that using cigarette smoking as a proxy of chronic exposure to nicotine may 
introduce a bias, as it is well known that tobacco includes, besides the nicotine, 
more than four thousand different constituents (Burns, 1991). Nevertheless, the effect 
of cigarette smoking on the central nervous system has been mainly attributed to 
the pharmacological action of nicotine (Dilsaver, 1987). 
Fourth, in the previous study all subjects were non-smokers and a comparison was 
made between subjects who received nicotine versus placebo via patches. In the 
present study smokers and non-smokers were compared. It might be that regular 
smoking, may increase the risk of an overreaction to suffocation signals and 
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therefore increase the risk for panic (Breslau and Klein, 1999; Pine et al., 2000; 
Caldirola et al., 2004). 
The results of the present study are in line with other experimental studies. Zvolensky 
et al. (2004) evaluated anxious and fearful responding to bodily sensations as a 
function of panic disorder and smoking status. Participants completed a voluntary 
hyperventilation procedure that elicits panic-relevant bodily sensations. At the pre-
challenge assessment, smokers with PD did not differ from non-smokers with PD on 
baseline anxiety. At the post-challenge assessment, smokers with PD reported 
greater levels of anxiety and bodily distress than non- smokers with PD. In our study 
smokers and non-smokers had also similar baseline anxiety scores, both on STAI and 
FQ scales. Lack of difference in the pre-challenge state anxiety between smokers 
with PD and non-smokers with PD rules out that smokers were more fearful following 
the challenge because of a higher baseline fear. Abrams et al. (2008) examined 24 
adult heavy smokers in 12-h nicotine withdrawal and 24 adult non- smokers on 
subjective and physiological reactivity to a 4-min carbon dioxide rebreathing 
challenge. Results indicated that smokers experienced a significantly greater 
increase in self- reported panic symptoms than non-smokers. 
Study limitations include lack of formal assessment of personality and of interrater 
reliability. 
In conclusion, the present findings are consistent with previous research that 
cigarette smoking appears to have the capacity to serve as a causal 
factor/facilitator in the development of PD. Cigarette smoking tends to precede the 
onset of panic and to promote panic itself, however the temporal pattern and the 
etiopathogenetic explanations of such a co-occurrence are still being discussed. 
Our results may have clinical implications, as smoking ces- sation might be a 
strategy in the prevention of panic (disorder) and could also be part of treatment 
strategy in PD. 
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Abstract 
 
Objective 
Cigarette smoking increases the risk of panic disorder with or without agoraphobia’s 
emerging. Although the cause of this comorbidity remains controversial, the main 
explanations are that (1) cigarette smoking promotes panic by inducing respiratory 
abnormalities/lung disease or by increasing potentially fear-producing bodily 
sensations, (2) nicotine produces physiologic effects characteristic of panic by 
releasing nor-epinephrine, (3) panic disorder promotes cigarette smoking as self-
medication, and (4) a shared vulnerability promotes both conditions. The aim of this 
review was to survey the literature in order to determine the validity of these 
explanatory models. 
 
Data sources 
 Studies were identified by searching English language articles published from 1960 
to November 27, 2008, in MEDLINE using the keywords: nicotine AND panic, tobacco 
AND panic,and smoking AND panic. 
 
Study selection 
Twenty-four studies were reviewed and selected according to the following criteria: 
panic disorder with or without agoraphobia and nicotine dependence, when used, 
diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, 
Third Edition, Revised, Fourth Edition, or Fourth Edition, Text Revision; no additional 
comorbidity or, if present, adjustment for it in the statistical analyses; use of adult or 
adolescent samples; comparison with a nonclinical control group or application of 
a crossover design. 
 
Data extraction 
 Non-significant results or trends only were reported as no difference. Data on 
anxiety disorders or substance abuse in general were not included. 
 
Data synthesis 
Panic and cigarette smoking each appear to have the capacity to serve as a 
causal factor/facilitator in the development of the other. Although the temporal 
pattern and the pathogenetic explanations of such a co-occurrence are still being 
discussed, cigarette smoking tends to precede the onset of panic and to promote 
panic itself. 
 
Conclusions 
Additional studies are strongly recommended. 
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Inroduction 
 
A disproportionate number of people with panic, in the form of either panic attacks 
or panic disorder, smoke cigarettes compared to those in the general population1,2 
and to individuals with other anxiety disorders.3 The temporal pattern underlying 
such a co-occurrence is still a matter of debate. Indeed, although panic can been 
associated with smoking and nicotine dependence 4–8 according to a bidirectional 
temporal pattern (going from smoking to panic or from panic to smoking),7 clinical 
and experimental data have suggested that cigarette smoking increases the risk of 
panic disorder’s emerging.9 Similarly, longitudinal studies 3–10 have supported the 
more common pattern of primary smoking and secondary panic occurrence. 
Several explanations have been proposed for this relationship: (1) cigarette smoking 
may lead to the onset of panic by inducing respiratory abnormalities 11–13 or lung 
disease. Thus, smoking may increase the risk of panic because, according to the 
false suffocation alarm theory,10,14 it induces an overreaction to suffocation signals; 
(2) nicotine may produce physiologic effects characteristic of panic attacks by 
promoting the release of norepinephrine into the brainstem 15; (3) smoking may 
modify the expression of panic disorder by increasing potentially fear-producing 
bodily sensations.16 Thus, individuals with panic disorder who usually perceive 
themselves as being physically unhealthy would more likely react with exaggerated 
anxiety.  
A different, less frequent, reverse pathway of primary panic and secondary nicotine 
dependence cannot be excluded.7 One hypothesis for this pathway is that panic 
disorder patients smoke as a means of self-medicating their symptoms, 1,17 because 
of the anxiolytic (pharmacologic) effects of nicotine 18 or because of cognitive 
mechanisms (smoking narrows the focus of attention and diverts one from stressful 
cognitions).19 
A shared vulnerability has been also advanced suggesting that personality, and in 
particular neuroticism, may be responsible for such a co-occurrence. 20 
Finally, according to Berkson’s bias (ie, a type of selection bias that may occur in 
case-control studies when controls are selected within the hospital instead of from 
the general population), the illusion of relationship due to an overrepresentation of 
patients with both disorders can be hypothesized. However, this potential for bias 
applies only to clinical studies and not to those conducted in community samples. 
Since matters may not be that clear-cut, the present article reviews the existing 
data on comorbidity between cigarette smoking/nicotine dependence and panic 
(either panic attacks or panic disorder with or without agoraphobia). The aim is to 
get a broader perspective on the relationship between panic and cigarette 
smoking and to identify the possible underlying etiologic mechanisms. 
 
Method 
 
A computerized search was carried out (PUBMED1960–2008) using the key words 
nicotine AND panic, tobacco AND panic, and smoking AND panic. In addition, the 
reference lists from existing reviews and from the articles retrieved were inspected. 
Only English language articles published in peer-reviewed journals were included. 
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We included studies in the general population, in panic disorder with or without 
agoraphobia/panic attacks patients, and studies adopting experimental models for 
panic disorder, as these latter are particularly suited to elucidate possible underlying 
mechanisms of the co-occurrence between smoking and panic. 
In epidemiologic surveys, statistical analyses had to be adjusted for comorbid 
psychiatric disorders different from nicotine dependence, if present. 
In the general and clinical population studies, the diagnosis of panic disorder with or 
without agoraphobia had to be made according to the Diagnostic and Statistical 
Manual of Mental Disorders Third Edition, Revised (DSM-III-R),21 Fourth Edition (DSM-
IV),22 or Fourth Edition, Text Revision (DSM-IV-TR).23 The definition of panic attacks 
had to conform to those proposed by the DSM-III-R, DSM-IV, or DSM-IV-TR. 
A control group or a crossover design was required, except in epidemiologic 
surveys. 
Studies were excluded when the data referred to anxiety disorders or substance use 
disorders in general. 
In order to work with the most conservative approach possible, non-significant 
results or trends were reported as no difference. 
 
Results 
 
Twenty-four studies, of the 61 screened, met our inclusion criteria. First, we present 
an overview of studies estimating the prevalence of the co-occurrence of cigarette 
smoking/ nicotine dependence and panic attacks/panic disorder with or without 
agoraphobia. Second, we offer an overview of studies that examined the 3 causal 
models (from panic to smoking, from smoking to panic, and shared vulnerability) in 
turn. Finally, experimental studies using laboratory panic provocation procedures will 
be considered. These studies focus on the underlying mechanisms of the 
panic/smoking link. 
To assist the reader, we report, in Table 1, the samples under study and the 
definitions of smoking status used and, in Table 2, the parameters measured and the 
primary results obtained in the studies included in the present review. 
 
Co-Occurrence of Panic and Smoking 
In an epidemiologic survey,24 the lifetime frequency of panic disorder was higher 
among smokers than nonsmokers for women, while no difference was found for 
men. Moreover, in a subsample of the National Comorbidity Survey (NCS),25,26 
current and lifetime smokers had significantly higher rates of panic disorder with or 
without agoraphobia than respondents from the general population, when either 
lifetime or past-month occurrence was evaluated. Thus, subjects exposed to 
smoking, either currently or throughout their lifetimes, are at a higher risk of 
experiencing panic than the general population. 
Studies conducted in clinical samples seem to confirm such a co-occurrence. 
Zvolensky et al16 found that smokers who had panic disorder with or without 
agoraphobia reported a higher level of anxiety than nonsmokers who had panic 
disorder with or without agoraphobia. The authors proposed that smoking modifies 
the expression of panic disorder with or without agoraphobia by promoting more 
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severe emotional disturbances. Indeed, smoking may confer a negative effect for 
specific anxiety-related symptoms, enhancing anxiety symptoms and worry about 
them. From this perspective, Zvolensky and coworkers suggested that smokers with 
panic disorder would not be more likely to have panic attacks than nonsmokers with 
panic disorder but would experience more frequent anxiety symptoms. 
Four studies have compared the specificity of smoking and panic disorder versus 
other anxiety disorders. In a national household survey in Great Britain,27 the preva-
lence of panic disorder in the nicotine-dependent population was significantly 
higher than in the nonnicotine–dependent population. Similar results were found for 
generalized anxiety and phobias. 
With regard to the clinical samples, the prevalence of cigarette smoking was 
investigated in 5 groups of outpatients (ie, depressive disorder, panic disorder, social 
anxiety disorder, other anxiety disorders, and comorbidity disorders).28 No significant 
differences were found. 
McCabe et al29 found different results when examining smoking behaviors among 
patients who had panic disorder with or without agoraphobia, social phobia, and 
obsessive-compulsive disorder (OCD). A significantly greater proportion of the panic 
disorder with or without agoraphobia group reported being a current smoker or a 
heavy smoker than the social phobia group and the OCD group. 
Finally, Goodwin and coworkers30 investigated the association between mental 
disorders and nicotine dependence among pregnant women. With regard to 
anxiety disorders, nicotine dependence significantly predicted the occurrence of 
panic disorder with or without agoraphobia, social phobia, specific phobia, and 
generalized anxiety disorder. However, after adjustments for demographic 
differences and comorbid Axis I and Axis II mental disorders were made, the only 
association that remained significant was between nicotine dependence and 
panic disorder with or without agoraphobia. 
In brief, a specific relationship between panic disorder with or without agora-phobia 
(vs other anxiety disorders) and cigarette smoking/nicotine dependence seems to 
be still a matter of debate. Only 2 studies of the 4 described above supported a 
unique relationship between panic disorder with or without agora-phobia and 
cigarette smoking/ nicotine dependence. 
 
From Panic to Smoking 
Isensee and coworkers7 prospectively evaluated adolescents and young adults. This 
is, to our knowledge, the only study showing that subjects with pre-existing baseline 
panic attacks or panic disorder have an increased risk for onset of nicotine 
dependence. 
 
From Smoking to Panic 
Breslau and coworkers1 evaluated a random sample of young adults and found 
that nicotine-dependent smokers are at a higher risk of developing panic than 
nonsmokers. Moreover, the higher the level of nicotine dependence, the higher the 
risk of panic. 
When the NCS23 and the Epidemiologic Study of Young Adults datasets10 were 
analyzed, a significantly higher risk of panic occurrence (either panic attacks or 
panic disorder) was found in subjects with pre-existing smoking if compared to 
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nonsmokers and in subjects who persist in smoking after panic onset compared to 
nonsmokers. 
Examining subjects with a history of panic and a history of daily smoking, Bernstein et 
al31 found that the earlier the age at onset of daily smoking, the greater the risk of 
developing panic disorder. 
Longitudinal studies have found similar results. In one study, adolescents who 
smoked 20 cigarettes or more per day were at elevated risk of panic disorder with 
agoraphobia during both adolescence and early adulthood when compared with 
those who smoked fewer than 20 cigarettes per day.3 
Nondependent regular smokers and dependent smokers were at higher risk of 
panic attacks than nonsmokers, and an elevated risk was maintained in dependent 
smokers when compared to occasional smokers.7 
Current smokers, with or without nicotine dependence, were at higher risk of panic 
disorder occurrence than non- smokers, while being a former smoker seemed to 
reduce such a risk. Examining the relationship between time elapsed since quitting 
and the risk of the first onset of panic disorder in past daily smokers, using a 
standardized variable that counts the number of years passed beginning with the 
year after quitting, researchers found that the likelihood of panic was reduced by 
one-half with each standard deviation unit of time elapsed since quitting.8 Thus, the 
authors showed some evidence that smoking cessation might reduce the risk of 
subsequent panic. 
Some hypotheses explaining the co-occurrence of smoking and panic have been 
proposed. Breslau and Klein10 suggested that lung disease might be one of the 
mechanisms linking smoking to panic. By increasing the risk of lung disease, smoking 
might indirectly increase the risk of panic attacks. In addition, they found that, 
according to the false suffocation alarm theory,14 cigarette smoking, by leading to 
chronic bronchitis and emphysema as well as to subclinical respiratory impairment, 
may favor panic attacks in subjects predisposed to overreaction to suffocation 
signals. Alternatively, they proposed that the carbon monoxide in cigarette smoke 
might affect the suffocation alarm threshold via inhibition of the carotid body.32 
Another interesting hypothesis was put forth by Leen-Feldner et al.33 Observing that 
smoking status was related to elevations in panic frequency among adolescents 
who were high in health fear, they suggested that, if a smoker experiences disease 
or illness, she or he may develop health fear, and exposure to smoke may increase 
attention to, and catastrophic misinterpretation of, bodily cues. Over time, the 
repeated pairing of fear with bodily cues may result in a learned association, such 
that somatic events ultimately elicit a panic-type response. 
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Examining clinical samples, Pohl et al17 showed a rate of smoking in patients with 
panic disorder with or without agoraphobia at its onset significantly higher than the 
one observed in healthy controls. They also found a strong gender effect. Indeed, in 
women, smoking may promote panic disorder onset and persistence; in men, 
smoking may protect against panic disorder occurrence, since it delays its onset. 
These results seem inconsistent with most of the findings presented here. Indeed, 
Pohl et al17suggested that smoking might be a risk factor for the development of 
panic disorder in women, while the relationship between cigarette smoking and 
panic disorder might not be a causal one in men. Thus, we argue that gender 
should be carefully considered in data analyses and interpretation of results. 
In Amering et al,2 smokers with panic disorder with or without agoraphobia were 
significantly younger at the onset of panic disorder with or without agoraphobia 
than non- smokers with panic disorder with or without agoraphobia. Thus, age at 
panic onset should be taken into account in clinical population studies as well as in 
clinical practice. 
Two studies have compared the specificity of smoking in promoting panic disorder 
among anxiety disorders. Johnson et al3 found that adolescents who smoked 20 
cigarettes or more per day were at elevated risk for generalized anxiety disorder, 
during both adolescence and early adulthood, and at elevated risk for 
agoraphobia and generalized anxiety disorder during early adulthood. Breslau et al8 
showed a 4 times greater risk of onset of agoraphobia when associated with pre-
existing smoking relative to nonsmoking. These results, consistent with other 
studies,27,29 suggest that smoking is linked uniquely to panic among anxiety disorders. 
 
Common Etiology of Shared Vulnerability 
Reichborn-Kjennerud et al34 investigated the hypothesis that a shared vulnerability 
can account for the relationship between cigarette smoking and panic. They 
examined shared genetic and environmental liability factors. The results suggest that 
genetic factors that influence panic and daily smoking appear to be distinct or 
weakly correlated, while shared environmental factors influencing the 2 phenotypes 
were highly similar. 
Finding consistent results, Agrawal et al35 examined monozygotic and dizygotic twin 
pairs and found that a history of panic attacks, together with other environ-mental 
factors (ie, parental education, parental smoking, early family influences, early life 
events, and conduct problems), was a significant predictor of regular cigarette 
smoking. 
Goodwin and colleagues36 focused more on heritabilitythan environmental factors. 
They showed evidence of an interaction between parental smoking and parental 
anxiety’s influencing the risk of co-occurrence of cigarette smoking and panic 
attacks among offspring. The authors propose possible explanations: (1) offspring 
with higher levels of parental anxiety disorders have an inherited (either genetic or 
environmental) vulnerability to anxiety, thereby they develop anxiety and 
subsequently begin smoking as a means of self-medication; (2) other behavioral 
factors associated with anxiety (eg, alcohol consumption) may increase the risk of 
cigarette smoking initiation; (3) initiation of cigarette smoking among individuals 
who are vulnerable to anxiety disorders may lead to development of panic attacks 
through anxiogenic effects or changes in respiratory functioning, and this risk may 
be more pronounced among those with a familial vulnerability to anxiety disorders; 
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and (4) the risk of panic related to parental cigarette smoking may be, in part, 
attributable to changes in respiratory function resulting from exposure to 
environmental tobacco smoke early in life. 
A moderational model studying neuroticism as a possible factor linking smoking and 
panic disorder was applied to a subsample of the NCS.37 Current smokers high in 
neuroticism (ie, a generalized tendency to experience negative affect) smoked 
greater numbers of cigarettes per day and were the most apt to have a lifetime 
diagnoses of panic disorder. No such moderating effects were apparent for other 
anxiety disorders. According to Zvolensky and coworkers,37 these data suggest that 
individual differences in theoretically relevant physiologic vulnerability factors (such 
as neuroticism) may amplify the effects of smoking in terms of panic-related 
problems. 
 
Mechanisms Underlying the Panic/Smoking Link 
The question of whether neurobiologic effects induced by serotoninergic agents are 
affected by the smoking status of panic disorder with or without agoraphobia 
patients was examined by Brooks et al.38 The patients under study underwent a 
neuropharmacologic challenge with ipaspirone, a selective 5-hydroxytryptamine-1A 
receptor agonist, and a placebo according to a crossover design. In the group of 
panic disorder with or without agoraphobia smokers, the ipaspirone-induced 
increases in cortisol concentrations were about twice as high as in the nonsmoker 
group. Brooks and coworkers suggested controlling for smoking status in 
neuroendocrine challenge studies when comparing patients with different 
psychiatric disorders or patients with healthy controls. According to them, nicotine 
has to be considered as a psychopharmacological comedication exerting its own 
effects on certain brain receptors. 
Zvolensky et al39 evaluated anxious and fearful responses to bodily sensations as a 
function of panic disorder and smoking status. Participants completed a voluntary 
hyperventilation procedure that elicits panic-relevant bodily sensations. At the 
postchallenge assessment and recovery period, smokers with panic disorder 
reported greater levels of anxiety and bodily distress than smokers without panic 
disorder and nonsmokers with panic disorder. These findings suggested a slower 
recovery in term of anxiety for smokers with panic disorder than for nonsmokers with 
panic disorder. Thus, among subjects with panic disorder, a history of regular 
smoking is related to an increased risk of prolonged anxious responding to bodily 
sensations. 
In recent years, experimental psychiatry has developed different paradigms that 
allow one to provoke panic in an experimental setting. The CO2 inhalation 
procedure has proven to be a specific, valid, reliable, and safe way to produce 
experimental panic.40 It appears that healthy individuals display a distinct 
behavioral vulnerability to increasing levels of acute hypercapnia. This effect is dose 
dependent, and it shares a striking similarity with the psychiatric condition of panic.41 
Cosci et al42 tested whether nicotine has a direct influence on laboratory-elicited 
panic in healthy nonsmoking volunteers. Subjects underwent a 35% CO2 challenge 
after transdermal administration of a nicotine or placebo patch, according to a 
crossover design. Compared to the placebo condition, nicotine increased heart 
rate and panic symptoms prior to the CO2 challenge but did not affect response to 
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the CO2 challenge itself. The change in physiologic measures before the challenge 
was attributed to nicotine’s impact on autonomic activation. 
In a study employing the Read rebreathing method, Abrams and colleagues43 
examined heavy smokers in withdrawal and nonsmokers on subjective and 
physiologic reactivity to a 4-minute, 5% CO2 challenge. Under the challenge 
condition, smokers experienced greater subjective breathlessness than did 
nonsmokers. Despite decreased respiration during the challenge, smokers 
experienced a significantly greater increase in self-reported cognitive and somatic 
panic symptoms than nonsmokers. The authors suggested that the findings are 
consistent with the idea that smoking may promote fearful responses to somatic 
sensations and, hence, may reflect a panic vulnerability factor. 
Although Cosci et al42 and Abrams et al43 evaluated subjects without a diagnosis of 
panic disorder with or without agoraphobia, the 2 studies were not excluded since 
they are, to our knowledge, the only reports in the literature using a CO2 challenge 
aimed at clarifying the relationship between smoking and panic. 
Experimental studies are strongly heterogeneous in their methods but not in their 
results. They generally show that regular nicotine use in cigarette smokers or 
nicotine-dependent individuals leads to exaggerated challenge response, although 
nicotine use in nicotine-naive individuals does not.42 
 
Discussion 
 
Panic and cigarette smoking each appear to have the capacity to serve as a 
causal factor/facilitator in the development of the other. For example, the bulk of 
the literature supports a strong relationship between smoking and panic. Few studies 
are in disagreement. For instance, Black et al24 found no difference in panic 
occurrence between smokers and nonsmokers, but when the sample was stratified 
by gender, they observed such a difference in females. Further studies clarifying the 
role of gender are warranted. 
A large body of literature suggests a specific relationship between smoking and 
panic relative to other anxiety disorders,* while few authors found such a relationship 
valid between smoking and other anxiety disorders.3,7,8,27,28 
However, it is worth noting that 5 of the 11 epidemiologic studies presented here 
were conducted within the frame- work of the NCS.26 While the studies referring to 
the NCS sample strongly support the hypothesis of a specific relationship between 
smoking and panic, the majority of those referring to non-NCS samples also suggest 
a link with other anxiety disorders. Thus, the results may have been influenced by the 
sample under study. Further investigations in samples other than that of the NCS, as 
well as investigations comparing subjects with different affective diagnoses, are 
warranted. 
The pathogenetic explanations of the co-occurrence between cigarette smoking 
and panic, highlighted in the studies presented here, refer mainly to 3 hypotheses. 
!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!*References 1, 2, 10, 16, 17, 25, 29, 31, 34-39 !
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According to a moderational model, neuroticism is a third factor linking smoking to 
panic, as it moderates smoking frequency in subjects with a lifetime history of 
panic.37 
According to a pathoplastic model of dysfunction, smoking is a vulnerability 
variable that modifies the expression of panic disorder by exacerbating affective 
disturbances and negative health processes.16,33,43 Finally, according to the false 
suffocation alarm theory, smoking, by increasing the risk of lung disease or 
impacting the carotid body, may induce an overreaction to suffocation signals and 
indirectly increase the risk of panic.10 The first 2 hypotheses have been supported by 
several studies. However, replication studies mainly derive from the research group 
of Zvolensky and coworkers16,33,37 or groups in joint venture with them.43 Independent 
groups may lend support to the findings obtained. 
With regard to the role of neuroticism, studying the personality of smokers versus 
nonsmokers who have panic disorder with or without agoraphobia would be fruitful. 
The idea that smoking may promote fearful responses to somatic sensations could 
be further developed in order to understand the mechanism by which this process 
might occur and, hence, help to identify high-risk individuals. For example, it would 
be interesting to engage comorbid individuals at different levels of nicotine 
dependence in biologic challenges. Finally, the nature of the respiratory 
abnormalities in smokers/nonsmokers who have panic disorder with or without 
agoraphobia and healthy smokers/healthy non- smokers should be compared to 
better understand the role of smoking in inducing clinical or subclinical 
abnormalities that may favor panic occurrence. 
Some authors found a unidirectional relationship going from smoking to panic 1,2,8,31 
Several causal mechanisms may explain this temporal relationship: (1) the biologic 
models according to which nicotine influences several neurochemical systems, (2) 
the cognitive perspective of panic attacks, and (3) the cardiovascular effects of 
nicotine misinterpreted as signs of danger, thus triggering panic attacks according 
to the Klein model.14 
On the other hand, only one study showed a bidirectional relationship between 
smoking and panic.7 
Some authors found a unidirectional relationship going from smoking to panic 1,2,8,31 
Several causal mechanisms may explain this temporal relationship: (1) the biologic 
models according to which nicotine influences several neurochemical systems, (2) 
the cognitive perspective of panic attacks, and (3) the cardiovascular effects of 
nicotine misinterpreted as signs of danger, thus triggering panic attacks according 
to the Klein model.14 
On the other hand, only one study showed a bidirectional relationship between 
smoking and panic.7 
Experimental studies have been strongly heterogeneous in their methods but not in 
results. With the exception of Cosci et al,42 they have consistently found that 
cigarette smoking increases fear reactivity to a biologic challenge, both in panic 
disorder patients and healthy volunteers. Cosci et al42 found that nicotine causes an 
autonomic activation before a biologic challenge without affecting the response to 
the challenge itself. However, they studied nonsmokers, rather than smokers and 
nonsmokers, acutely exposed to nicotine or placebo.43 Assuming that higher doses 
of CO2 activate the same physiologic chain of events in panic-free individuals, CO2 
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challenges may have a strong potential as a substitute for early clinical trials in 
testing novel pharmacologic compounds.41 
A few studies evaluated patients with a formal diagnosis of nicotine 
dependence.1,7,8,27 Among these studies, consistency was found. Breslau et al1 and 
Isensee et al7 showed that the more severe the level of nicotine dependence, the 
higher the risk of comorbidity with panic. Farrell et al27 and Isensee et al7 found an 
association not only between nicotine dependence and panic but also between 
nicotine dependence and generalized anxiety disorder. 
It is quite surprising that, although cigarette smoking has been classified among 
substance use disorders since the 1980s,23,45 only a minority of studies in the present 
review referred to this formal diagnosis. Researchers more often defined cigarette 
smoking according to heterogeneous criteria; less often they assessed nicotine 
dependence via specific instruments, and only rarely did they use the diagnostic 
criteria for nicotine dependence. Thus, cigarette smoking seems to be considered a 
habit of life rather than a disorder. In this framework, it would be desirable to have a 
larger number of studies assessing nicotine dependence and using the formal 
diagnosis. This approach would focus on cigarette smoking as a clinically relevant 
disorder and shed some light on the pathogenetic mechanisms of the co-
occurrence between nicotine dependence and panic. Moreover, this approach 
might have interesting implications for clinical practice and research. In clinical 
practice, it might encourage health care workers to consider cigarette smoking as 
a substance use disorder rather than as a habit of life, favor a proper diagnostic 
assessment, and promote quitting as well as preventive strategies. For research 
purposes, the use of similar inclusion criteria would very likely improve comparability 
between studies. 
 
Conclusions 
 
The above evidence suggests that a lifetime association between daily smoking 
and panic does exist and might reflect causal mechanisms. 
Nicotine is a complicated molecule that promotes turnover of several 
neurotransmitters (eg, acetylcholine, dopamine, norepinephrine) and upregulates 
the receptors in critical brain areas (eg, the locus ceruleus, mesolimbic 
dopaminergic pathway). 
The following additional studies are warranted: (1) epidemiologic and clinical 
studies comparing male and female subjects, (2) epidemiologic surveys utilizing new 
samples, (3) clinical studies comparing the relationship between smoking and panic 
with the relationship between smoking and other anxiety disorders, (4) experimental 
studies conducted in independent laboratories, (5) replication of studies focusing on 
shared vulnerability, and (6) systematic use of the diagnosis of nicotine 
dependence. 
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Abstract 
 
Background  
We investigated the efficacy of an intensive 1-week behavioral therapy program 
focusing on agoraphobia for panic disorder patients with agoraphobia (PDA). 
 
Design and method 
The study design was a case-control study. Main outcome measure was the 
agoraphobia score of the Fear Questionnaire (FQ-AGO). The outcomes on the FQ- 
AGO of a 1-week intensive therapy (96 patients) and a twice-weekly therapy (98 
patients) were compared. 
 
Results 
Agoraphobia improved significantly in both groups, 1 week and 3 months after 
therapy. Effect size for changes in the 1-week intensive therapy on the FQ-AGO was 
0.75. 
 
Limitations 
Limitations are use of antidepressants, no placebo group, no long term follow-up. 
 
Conclusion 
Behavioral therapy for agoraphobia can be shortened significantly if intensified 
without affecting therapy outcome, thus allowing patients a more rapid return to 
work and resumption of daily activities. 
 
Key words: Panic disorder, agoraphobia, behavioral therapy, expanding-spaced 
exposure, intensive exposure therapy, massed-exposure therapy 
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Introduction 
 
Panic disorder with agoraphobia (PDA) is an invalidating condition that causes high 
health care consumption (Barsky et al, 1999; Lepine, 2002; Roy-Byrne et al, 2002; 
Roy-Byrne et al, 1999; Roy-Byrne et al, 2005; Smit et al, 2009; Zaubler and Katon, 
1998). It is associated with higher societal costs compared to other mental disorders 
regarding direct medical, direct non-medical and indirect non-medical costs (Rees 
et al, 1998). These costs are even higher if panic disorder is accom-panied by 
agoraphobia (Batelaan et al, 2007). Several effective therapies are now available 
for agoraphobia (Sanchez-Meca et al, 2010), mainly cognitive and behavioral 
therapy (CBT). It is clear that the shorter the duration of the therapy, the sooner the 
patient can return to his or her normal daily activities, including work.  
The present study describes the efficacy of a brief, intensive, clinician-guided 
exposure program for severe agoraphobia and compares it to a form of behavioral 
therapy involving twice-weekly contacts with a therapist. 
 
Methods 
 
Subjects 
The sample consisted of 194 patients who were recruited from the Academic 
Anxiety Centre in Maastricht, an outpatient clinic in the Netherlands. Diagnosis 
according to DSM IV criteria was made by an experienced psychiatrist via 
psychiatric interview. Only patients with panic disorder with severe agoraphobia as 
primary diagnosis were included. Exclusion criteria were being on psycho-tropic 
medication (with the exception of antidepressants), severe depressive disorder, 
suicidal intent, psychosis, substance abuse or cognitive impairment. 
Of the 194 patients, which were included in the study, 96 PDA-patients completed 
the 1-week in vivo exposure-based behavior therapy program for PDA. This was the 
experimental group. The matched, historical-control subjects were 98 PDA-patients 
who completed a twice-weekly therapy program that formerly was the regular 
treatment at our Academic Anxiety Center. 
The study design was a case-control study. The case group consisted of 96 patients. 
The control group was obtained using data from patients who followed therapy 
before the introduction of the intensive program. Data from those 98 PDA patients 
were selected after matching for age, sex, co-morbidity and the use of 
antidepressants (the antidepressant compound distribution among the 2 treatment 
groups was as follows, case group and control group respectively: fluvoxamine, 23 
and 23; paroxetine, 51 and 51; clorimipramine 1 and 1; sertraline 3 and 1, fluoxetine 
3 and 1, moclobemide 1 and 3; citalopram, 4 and 0; trazodone, 1 and 0; 
desipramine, 0 and 2) . All medication was kept constant, according to the 
treatment protocol. 
Of the 98 patients in the control group, 69 were women and 29 were men. The 
mean age was 40.01 ± 10.68. Of those 98 patients, 89 patients were taking an 
antidepressant and 27 patients had a concurrent psychiatric disorder; 13 patients 
had depressive disorder, 4 patients dysthymic disorder, 1 patient specific phobia 
and the rest of the 27 patients had combinations of comorbidity (such as depressive 
disorder, social phobia).  
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Of the 96 patients in the case group, 73 were women and 23 were men. The mean 
age was 37.98 ± 9.09. Of those 96 patients, 83 patients were taking an 
antidepressant and 28 patients had a concurrent psychiatric disorder; 14 patients 
had depressive disorder, 1 patient obsessive compulsive disorder (OCD), 1 patient 
specific phobia and the rest of the 28 patients had combinations of comorbidity 
(such as depressive disorder, social phobia, OCD). 
 
Procedures 
The diagnosis of PDA was established in a clinical interview by an experienced 
psychiatrist following the criteria of the DSM-IV (American Psychiatric Association. 
and American Psychiatric Association. Task Force on DSM-IV., 2000). Patients also 
had a medical history inventory and an evaluation through the Mini International 
Neuropsychiatric Interview (Sheehan et al, 1998) to support the diagnoses.  
Psychometric evaluation involved the Fear Questionnaire (FQ) (Marks and Mathews, 
1979), the Clinical Anxiety Scale (CAS) (Snaith et al, 1982), and the Montgomery-
Åsberg Depression Rating Scale (MADRS) (Montgomery and Asberg, 1979). The FQ 
measures phobic avoidance on three subscales on agoraphobic, social phobic 
and blood-injury related avoidance (Cox et al, 1995; Marks et al, 1979). Only the 
total FQ-score (FQ-tot, range 0-120) and the score of the subscale ‘agoraphobia’ 
(FQ-AGO, range 0-40) were included in the present study. The researcher who 
assessed the measures was independent of therapy. 
The treatment under investigation was the 1-week in vivo exposure- based behavior 
therapy program (‘the case group’) which consisted of 5 full consecutive days of 
cognitive behavioral therapy. Patients stayed in an inn overnight, while their days 
were devoted to exposure to several agoraphobic situations. First, the patient 
received psycho-education on panic disorder and agoraphobia as well as the 
rationale of exposure therapy. At the beginning, exposure was conducted under full 
coaching by a behavioral therapist. The coaching was gradually reduced during 
the week. 
The control condition (‘the control group’) was a twice-weekly therapy program, 
which consisted of 12 sessions exposure therapy sessions, spread over 6 weeks. The 
focus of both forms of treatment was on the element of exposure (Sanchez-Meca et 
al, 2010). 
Both therapies included homework and a follow-up program. By practice in their 
home/daily environment, patients learned to integrate their experiences in other 
more natural contexts where they used to avoid feared situations. The same 
therapists trained in behavioral therapy conducted both therapies. All therapies was 
delivered individually. The amount of face to face time with a therapist did not differ 
substantially between groups: 23 h in the intensive group versus 23 in the 
comparison group. Psychometric data were gathered 1 week before and one 
week after treatment and 3 months after.  
 
Data analysis 
Data were analyzed using repeated-measures analysis of variance (ANOVA) with 
time as the within-subjects factor and type of therapy as the between-subjects 
factor. The effect size was calculated for FQ-AGO changes in the intensive group. 
The results were based on a last observation carried forward analysis. 
!! 69!
 
Results 
 
Outcome scores before, 1 week after, and 3 months after therapy are shown in 
Table 1. Scores of the MADRS and CAS at pre-treatment were significantly higher in 
the case group. Pre-treatment scores of FQ-tot and FQ-AGO did not differ 
significantly between groups. 
ANOVA of the FQ-AGO scores before, 1 week after, and 3 months after therapy 
showed a significant improvement in both groups, as can be seen in Figure 1. Effect 
size for changes in the case group on the FQ-AGO was 0.75. Time*group interactions 
were not significant for the FQ-AGO. 
With regard to the FQ-tot, the MADRS, and the CAS, ANOVA showed a significant 
improvement in scores on all scales in both groups. Time*group interactions were 
not significant for the FQ-tot or the MADRS, but they were significant for the CAS, 
with a stronger improvement in the case group. 
 
Table 1. Outcome scores before, 1 week after, and 3 months after therapy. 
 Case group Control group 
 Pre- 
Treatment 
Post- 
Treatment  
3-months 
after 
therapy 
Pre- 
Treatment 
Post-
treatment  
3-months 
after 
therapy 
MADRS 13.0 (6.1) 7.4 (6.0) 7.1 (6.0) 9.2 (7.7) 4.5 (5.7) 4.5 (5.4) 
CAS 11.6 (4.4) 5.5 (4.5) 5.4 (4.8)  7.9 (5.5)  3.7 (4.2) 3.6 (4.3) 
FQ-tot 52.4 (21.6) 20.4 (14.3) 19.3 (15.9) 57.8 (21.1) 27.2 (21.7) 27.2 (23.0) 
FQ-
AGO 
25.0 (9.8) 5.6 (6.5) 5.5 (10.0)  27.6 (9.0) 9.6 (10.3) 9.9 (10.7) 
MADRS: Montgomery–Åsberg Depression Rating Scale; CAS: Clinical Anxiety Scale; FQ-tot: Fear 
Questionnaire total score; FQ-AGO: Fear Questionnaire ‘agoraphobia’ subscale score 
 
Limitations 
 
Several limitations of our study need to be mentioned. First, some of the patients 
were taking an antidepressant. Hence, symptoms were still present in spite of 
medication. We therefore cannot completely exclude the possibility that 
medication status may affect treatment outcome. However, an effect of 
medication is rather unlikely, given that patients were on a constant dosage for 2 
months prior to inclusion and medication was kept constant during treatment. 
Moreover, subjects in the control group were matched on the use of 
antidepressants. Second, no placebo group was incorporated. Third, since the 
follow- up data are limited to 3 months, it is not possible to evaluate treatment 
effect beyond this period. Both therapy programs however, included homework, 
leading to generalization of fear extinction by extending the treatment out of the 
therapeutic context, thereby contributing to a more profound treatment effect 
(Sanchez-Meca et al, 2010). Fourth, patients were not randomly allocated to one of 
the two treatment programs. However, the data of the control group were selected 
after matching for age, sex, co-morbidity, and the use of antidepressants. 
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Fig 1. Fear questionnaire-agoraphobia scores (FQ-AGO) before and after treatment 
with intensive versus classical CBT. 
 
Discussion 
 
This study demonstrated the efficacy of a 1-week intensive behavioral treatment for 
panic disorder with agoraphobia. Previous studies on the efficacy of intensive 
therapy versus expanding-spaced exposure have produced mixed results. Lang 
and Craske (2000) found no differences between a 1-day exposure program and a 
program with several sessions in 1 week at 1 month of follow-up. However, the 
interval between the sessions may have been too short to differentiate between the 
two. Chambless (1990) also found no differences in agoraphobic scores over a 6-
month period between ten daily and ten weekly sessions of exposure in 19 
agoraphobic patients. On the other hand, Foa et al (1980) compared the efficacy 
of ten daily sessions of behavior therapy versus ten once-weekly sessions in 11 
agoraphobic patients. They found the massed procedure to be superior in reducing 
agoraphobic avoidance and suggested that this might have been due to the lack 
of opportunity in this group to engage in avoidance behavior between sessions. 
Hahlweg et al (2001) studied the effectiveness of 2-3 week daily exposure in 416 
PDA patients. Results 6 weeks and 1 year after therapy showed significant 
reductions in agoraphobic avoidance. No control group was included. Deacon 
and Abramowitz (2006) found significant reductions in panic disorder symptoms in 
10 PD patients, 5 of whom with PDA, after a 2-day cognitive behavioral therapy 
including cognitive restructuring and exposure in vivo. In a meta-analysis Sanchez-
Meca et al (2010) found no relationship between the duration of the therapy and 
the effect size. 
Together with our results, these studies show that behavioral therapy for 
agoraphobia can be shortened if intensified without affecting therapy outcome. It 
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has been suggested by Lang et al (2000) that expanding-spaced exposure could 
be superior in reducing agoraphobia due to exposure to varied contextual stimuli 
relative to massed exposure. Exposure to varied contextual stimuli may lead to a 
greater generalization of extinction and less return of fear. The fact that subjects in 
our case group were exposed to a broad variety of cues may have led to the 
positive results in the short and longer term. 
 
Conclusions 
 
In conclusion, the 1-week CBT program for agoraphobia allows a more rapid 
reduction of symptoms with an equally successful therapy outcome. This may result 
in a more rapid return to work and resumption of daily activities. Another advantage 
of the time-limited, concentrated design of the 1-week CBT, might be the access to 
therapy. The availability of an intensive therapy program may not only benefit 
individual patients, but also have economic returns for society. In attempt to 
provide cost-effective treatment, the exploration of strategies to shorten the 
duration of therapy is necessary. 
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Abstract 
 
Background 
The last decades many studies have shown that cognitive behavioral therapy (CBT) 
is highly effective for the treatment of panic disorder with agoraphobia (PDA). There 
is a high degree of comorbidity between PDA and depression. However, studies 
examining treatment outcome for panic disorder with comor-bid depression have 
produced mixed results.  
The goal of this study was to assess the degree of comorbidity between PDA and 
major depression (MD) in a large outpatient sample and to examine the influence 
of comorbid MD on treatment outcome for PDA.  
 
Method 
Participants were patients referred to an out-patient setting specialized in anxiety 
disorders. Patients, who met criteria for panic disorder with agoraphobia and 
completed baseline assessment, were enrolled in the study (N = 689).  
For depressive symptoms the Montgomery–Asberg Depression Rating Scale (MADRS) 
was applied. For PDA symptoms, the Panic and Agoraphobia Scale (PAS) and the 
subscore for agoraphobia (FQ-AGO) of the Fear Questionnaire were used.  
The group that completed the post-treatment assessment was analyzed cate-
gorically as well as dimensionally regarding the influence of depression by dividing 
into 2 groups (comorbid MD or not) or 3 groups (according to their MADRS- score). 
These groups were then compared regarding their PDA- and depression outcomes 
at baseline and post-treatment.  
 
Results 
Of 689 patients that were enrolled in the study, 421 entered manualized behavioral 
therapy of which 288 completed the post-treatment assessment. Of these 288 
patients, one third had MD (N = 87).  
Symptom severity on PDA symptoms at baseline was significantly different between 
depressed and non-depressed PDA patients. Both depressed and non-depressed 
PDA patients responded well to behavioral therapy as reflected in post-treatment 
assessments for depressive and PDA symptoms. Moreover, depressed PDA patients 
showed even larger improvement than non-depressed PDA patients on the PAS and 
the MADRS.  
 
Conclusion 
Depression frequently accompanies PDA and appears not to affect treatment 
outcome negatively. Moreover, the depressive symptoms were reduced after 
manualized behavioral treatment focused on the PDA. 
 
Key words: Panic disorder, agoraphobia, depressive symptoms, major depression, 
behavioral therapy 
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Introduction 
 
Clinical studies have demonstrated that different diagnoses may coexist. A large 
number of epidemiological studies have shown a relationship between anxiety and 
mood disorders (Angst 1996; Regier et al.,1998). 
Psychiatric comorbidity is typically defined as the co-occurrence of two or more 
psychiatric disorders within the same individual (Maser and Cloninger 1990). Several 
studies have shown that depression is a frequent comorbid complication of PDA 
patients (Goodwin et al., 2005; Kessler et al., 1998; Roy-Byrne et al., 2000; Wittchen et 
al., 1991). There is evidence that anxiety disorders are risk factors for depression and 
typically precede the onset of depression (Bittner et al., 2004; Goodwin 2002; 
Wittchen et al., 2003). Moreover, comorbid depression in PDA is associated with 
more severe panic- related symptoms (Allen et al., 2010; Rief et al., 2000). 
Epidemiological studies have shown a one year prevalence rate of PDA of around 
3% (Barr Taylor 2006) and a lifetime prevalence rate of 1.5% to 4.7% (Kessler et al., 
2006; Mendolowiz and Stein 2000). The lifetime prevalence rate for depressive 
disorders varies from about 8% (Regier et al., 1990) to 11.7% (Wittchen et al., 1999). 
Over a lifetime, about half of patients with panic disorder will develop depression 
(Barr Taylor 2006). In treatment studies of PD with or without agoraphobia, the 
comorbidity rate of depression varies between 12% to 47% (Brown et al., 1995; 
Emmrich et al.,2012; Skeketee et al., 2001; Tsao et al., 2005). 
The high comorbidity between PDA and depressive disorder gives rise to ques-tions 
regarding the influence of a comorbid depression on CBT focusing on the PDA. A 
clinical implication could be that response to treatment differs between patients 
with or without comorbid depression. 
The last decades, many studies have shown that cognitive behavioral therapy (CBT) 
is highly effective for the treatment of patients with panic disorder (Beck et al.,1994; 
Brown and Barlow 1995; Brown et al., 1996; Fava et al., 1995; Sánchez-Meca et al., 
2010; Telch et al., 1993). However, studies examining treatment outcome for panic 
disorder with comorbid depression have produced mixed results. While several 
studies have suggested that the presence of a concurrent depressive disorder is 
associated with lesser improvement (Brown and Barlow 1995; Grunhaus et al., 1994; 
O’Rourke 1996; Rosenberg and Hougaard 2005; Sánchez-Meca et al., 2010; 
Skeketee et al., 2001; Tsao et al.,1998), other studies suggested that comorbid 
depression does not negatively affect CBT focusing on PDA (Allen et al., 2010; Dow 
et al., 2007; Laberge et al., 1993; Maddock and Blacker 1991; Mc Lean et al., 1998; 
Rief et al., 2000; Tsao et al., 2002). 
There are several explanations for these mixed outcomes; the variability in assess-
ment procedures, small sample size and associated lack of power to demon-strate 
possible differences. Also, the tendency in scientific studies to examine 
homogeneous groups, led in many studies to the exclusion of patients with 
comorbid depression or to the inclusion of only a low rate of comorbid depression 
(Blanes and Raven 1995). However, since a comorbid depression in PDA patients is 
common, the generalizability of the results of some treatment studies can be 
questioned.  
Allen et al. (2010) and Rief et al. (2000) found that, despite having more severe 
panic disorder symptoms at pretreatment, individuals with comorbid anxiety and/or 
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depression were equally likely to respond to treatment as those without such 
depression. However, in the study of Rief et al. (2000) the end-state functioning of 
PDA patients with comorbid depression was significantly lower than for patients with 
panic disorder alone.  
Recently Emmrich et al. found (2012) that exposure- based cognitive behavioral 
therapy (CBT) for primary PDA effectively reduces anxiety and depressive 
symptoms, irrespective of comorbid depression or (severe) depressive symp-
tomatology. These results are in line with previous studies (Tsao 1998, Tsao 2002). On 
the other hand, in two other studies (Mc Lean et al., 1998; Woody et al., 1999) no 
significant reduction of depressive symptomatology was found. Those studies 
however excluded patients with any comorbid axis I disorder other than PD, AG or 
depression. Also, Allen et al. (2010), found that rates of MDD decreased, but this 
decrease did not reach statistical significance. 
Also, studies examining whether the presence of comorbidity is associated with 
more severe symptoms of PDA, have yielded conflicting results. Most studies (Allen 
et al., 2010; Brown et al.1995; Emmrich et al., 2012; Goodwin et al., 2005; Kessler et 
al., 1998; Rief et al., 2000; Tsao et al., 2002) found that PDA patients with a comorbid 
diagnosis were rated as having more severe panic symptoms than those without 
comorbidity. On the other hand, Tsao et al. (1998) found no such difference in their 
study which may have been due to relatively small sample size. 
Clinical studies often aim to include homogeneous subgroups, excluding many 
types of comorbidity, medication use etc, in search of clear differences between 
groups. It has been suggested that this approach leads to decreased genera-
lizability of results (Rief et al., 2000). The present study addresses the influence of 
comorbid depression on treatment effect for panic disorder in a more naturalistic 
way. We therefore chose not to use very restrictive inclusion criteria. Our goal was to 
present a sample that is representative for the treatment seeking patients in our 
outpatient setting. 
The current study aims to contribute to the knowledge of the relationship of 
comorbid MD and PD regarding symptom severity and treatment outcome. The 
principal aim of the present study was to investigate the effectiveness of 
manualized behavioral therapy in the treatment of patients with panic disorder and 
comorbid major depression (MD) compared to PD patients without MD. Hypotheses 
were formulated as follows: (1) the presence of a comorbid MD is reflected in more 
severe symptoms of PDA at baseline (2) patients with and without comorbid MD 
improve to a comparable degree (3) behavioral therapy for PDA also effectively 
reduces depressive symptomatology as measured with the MADRS. 
 
Methods 
 
Participants were recruited from an outpatient setting specialized in anxiety 
disorders in Maastricht, the Netherlands.  
Patients with the principal diagnosis of PDA according to DSM- IV criteria (APA,1994) 
were included for baseline assessments (N = 689). 
Diagnosis according to DSM IV criteria was made by two experienced psychiatrists 
via psychiatric interview, including the MINI (Mini International Neuropsychiatric 
Interview) (Sheehan et al, 1998).  
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Patients with psychiatric comorbidities were included for manualized behavioral 
therapy except those conditions expected to severely limit patient participation or 
adherence (suicidal intent, psychosis, substance abuse or cognitive impairment). 
The clinical assessment of fear was performed with two scales: The Fear 
Questionnaire (FQ) and the Panic and Agoraphobia Scale (PAS). The FQ is a self-
rating scale that assesses phobic avoidance. It produces a glo-bal score (FQ-tot, 
range 0-120) and subscores for agoraphobia (FQ-AGO, range 0-40), blood-injury 
phobia (FQ-BI, range 0-40) and social phobia (FQ-SOC, range 0-40) (Marks and 
Mathews, 1979). To assess overall severity of the panic symptomatology, the 
observer-rated version of the PAS was used (Bandelow et al, 1998). The PAS (range: 
0-52) contains 13 items grouped in five subscales: ‘Panic Attacks’ (including the 
items frequency, severity and durations), ‘Agoraphobia’ (including frequency, 
number and relevance of situations), ‘Anticipatory Anxiety’ (including frequency 
and severity), ‘Disability’ (including family, social relationships and employment) and 
‘Worries about health’ (including worries about health damage by panic attacks 
and assumption of organic disease). To assess the severity of co-morbid depressive 
symptoms, the Montgomery-Åsberg Depression Rating Scale (MADRS, range: 0-60) 
(Montgomery and Asberg, 1979) was used. 
The researcher who assessed the psychometric measures was independent of 
therapy. 
After the diagnostic procedure was performed, patients with panic disorder with 
agoraphobia as principal diagnosis received manualized behavioral therapy (N= 
421). The main method was exposure in vivo (Sánchez-Meca et al., 2010). Exposure 
in vivo is a technique consisting of gradually exposing the patient to feared 
situations by carrying out experiments.  
In those cases where comorbid MD prevented patients from being able to perform 
exposure exercises, those patients were offered an antidepressant (i.e., SSRI)’. 
The duration of the treatment was flexible depending on individual clinical 
progression, with an average of 12 weeks. Therapy duration and number of sessions 
did not differ significantly between groups. 
Discharge was planned by mutual agreement between patient, behavioral 
therapist and psychiatrist. At discharge, the initial psychometric assessment was 
repeated (post-treatment assessment).  
 
Participants. 
All patients who fulfilled the criteria of panic disorder with agoraphobia, and 
completed baseline assessment, were enrolled in the study (N = 689). Of these 421 
(61%) entered manualized behavioral therapy and 288 patients (68% of those who 
entered therapy) completed the post-treatment assessment.  
Of the 689 participants, 64% were female, 40% was on an antidepressant, 62.4% had 
a concurrent psychiatric disorder and 33% had current MD. The mean age was 39 (± 
12.5) years, the mean duration of the PDA 11.6 (± 11.2) years, the PAS 23.9 (± 10.3), 
the FQA 20.3 (± 12.3) and the MADRS 13.8 (± 8.2). Sociodemographic variables of 
the groups with and without comorbid MD are presented in table 1.  
Of the 421 patients who entered manualized behavioral therapy, 66% were female, 
40.7% was on an antidepressant and 33% had a comorbid MD. The mean age was 
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39 (± 12.3) years, the mean duration of the PDA 11.9 (± 11.5) years, the PAS 24.6 
(±10.1), the FQA 21.9 (± 11.7) and the MADRS 13.5 (± 7.9). 
Of the 288 participants group that completed the post-treatment assessment,  
67% were female, 36.5% was on an antidepressant, 62.2% had a concurrent 
psychiatric disorder and 30.5% had current MD. The mean age was 39.7 (± 12.3) 
years, the mean duration of the PDA 12.0 (±12.4) years , the PAS 24.1 (± 10.2), the 
FQA 21.9 (± 11.4) and the MADRS 13.2 (± 7.9). 
Data from the last group were analyzed for treatment effect.  
Sociodemographic variables of the groups with and without comorbid MD are 
presented in table 2. 
 
Statistics 
To examine the overall effect of treatment on changes in outcome measures, a 
one-way repeated-measures multiple analysis of variance (MANOVA) was con-
ducted on the FQ-AGO, PAS and MADRS with time (pre-treatment, post-treat-ment) 
as the within-factor. To examine the impact of depressive symptoms on response to 
treatment, a one-way independent multiple analysis of covariance (MANCOVA) 
was used on change scores on the FQ-AGO and PAS (pre minus post scores) with 
depression severity according to MADRS scores (0-6: symptoms absent, 7-19: mild 
depression, 19-34: moderate depression and 34-54; severe depression) as the 
between-factor and duration of illness (Sánchez-Meca et al., 2010) and use of 
antidepressant during treatment as covariates. For the analysis of baseline values a 
chi-square test was used for categorical variables (sex, co-morbidity, use of 
antidepressants) and a one-way ANOVA was used to compare the means of the 
non-categorical variables (age, duration of the PDA, FQ-AGO pre-treatment, FQ-
AGO post-treatment, PAS pre-treatment, PAS post-treatment, MADRS pre-treatment, 
MADRS post-treatment). The results are presented as means ± standard deviations 
and significance levels were set at p < .05 (two-tailed).  
 
Results 
 
Baseline values 
Table 1 shows the sociodemographic variables of the groups with and without 
comorbid MD at baseline. There were no significant differences considering sex and 
duration of PDA but there were differences found for age, use of antidepres-sants 
and co- morbidity (specific phobia, PTSS). There were also striking differences found 
for the PAS, FQA and MADRS.  
Table 2 presents the sociodemographic variables of the participants with and 
without comorbid MD who completed the post-treatment assessment. There were 
no significant differences considering sex, age and duration of the PDA but there 
were differences found for use of antidepressants (at baseline and during therapy) 
and comorbidity (dysthymic disorder, specific phobia, PTSS). Also here, striking 
differences were found for the PAS, FQA and MADRS at baseline. 
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Table 1. Sociodemographics and baseline values 
Variable  PDA with MD PDA without MD 
Significance P 
< 0.05 
 N   209 421  
Age. years 41.4 ± 12.5 38 ± 12.4 0.001 
Females.% 63 64.8 0.371 
Duration of the PDA. years 11.6 ± 10.8 11.7 ± 11.5 0.963 
Dysthymic disorder 0 23 0.000 
Adjustment disorder 0 7 0.102 
Bipolar disorder 2 3 0.668 
Psychotic disorder 2 4 1.000 
Agoraphobia  203 403 0.394 
OCD 13 17 0.236 
GAD 0 7 0.102 
Social phobia 23 27 0.059 
Specific phobia 27 89 0.016 
Somatoform disorder 17 33 0.877 
PTSS 23 12 0.000 
Eating disorder 5 4 0.165 
Antidepressant. % 47.4 36 0.004 
Smoking. % 59.2 41.9 0.000 
PAS 29.4 ± 9.3 21.3 ± 9.9 0.000 
FQA 24.4 ± 11.4 18.2 ± 12.2 0.000 
MADRS 21.8 ± 6.2 9.9 ± 5.9 0.000 
SDS 57.2 ± 9.2 43.8 ± 9.8 0.000 
 
 
There were no significant differences between the ‘completers’ and the ‘non- 
completers’ of the participants entering the manualized behavioral therapy 
considering age, sex,duration of the PDA, FQA at baseline and MADRS at baseline. 
There was a difference in antidepressant use (p = 0.02) and the PAS at baseline (24.1 
± 10.2 in the ‘completers’- group versus 26.9 ± 9.2 in the ‘non –completers’ group; p 
< 0.05). 
 
Post-treatment values  
Table 2 presents the mean FQ-AGO, PAS and MADRS post-treatment scores of the 
groups with and without MD who completed the post-treatment assessment. 
A significant effect of treatment on outcome measures was found [F(3, 198) = 
12.378, p < .0001]. Separate univariate ANOVA’s on the PAS and MADRS revealed 
significant treatment effects [F(1, 200) = 6.145, p < .014 and F(1, 200) = 36.718, p < 
.0001, respectively], but not on the FQ-AGO [F(1, 200) = .786, p = .373]. Manualized 
behavioral therapy reduced the intensity of panic symptoms as observed by a 
significant reduction on the PAS scores. Moreover, behavioral therapy focused on 
PDA also significantly reduced depressive symptoms. Parameter estimates reveal 
that compared to individuals without MD patients diagnosed as being depressed 
have larger PAS change score by 4.263 score-points (t = 2.249, p = .014). 
Interestingly, patients with the diagnosis of MD also had a larger MADRS change 
score by 6.780 score-points when compared to subjects who did not receive the 
diagnosis (t = 6.060, p < .0001). 
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Tabel 2. Sociodemographics values from ‘completers’ 
Variable  PDA with MD PDA without MD Significance P 
< 0.05 
 N   87 197  
Age. years 40.4 ± 13.1 39.1 ± 12.1 0.418 
Females. % (n) 64.4 (n=56) 70 (n=136) 0.438 
Duration of the PDA. years 11.4 ± 11.2 12.4 ± 12.4 0.586 
Antidepressant. % at baseline 45 (n=40) 32 (n=63) 0.214 
Antidepressant. % during 
therapy 
(n=58) (n=53) 0.000 
Smoking. % 53. 8 (n=43) 34.6 (n=66) 0.003 
Dysthymic disorder (n) 11 0 0.025 
Adjustment disorder 0 3 0.247 
Bipolar disorder 1 1 0.551 
Psychotic disorder 0 0  
Agoraphobia  87 190 0.075 
OCD 6 8 0.309 
GAD 0 2 0.346 
Social phobia 9 9 0.066 
Specific phobia 11 43 0.069 
Somatoform disorder 7 20 0.577 
PTSS 9 1 0.000 
Eating disorder 2 2 0.397 
PAS at baseline 29.7 ± 9.8 (n=84) 21.6 ± 9.5 (n=191) 0.000 
FQA at baseline 25.9 ± 9.8 (n=87) 20.2 ± 11.7 (n=196) 0.000 
MADRS at baseline 21.3 ± 5.9 (n=86) 9.7 ± 5.8 (n=197) 0.000 
SDS at baseline 55. 9 ± 9.4 (n=86) 43.4 ± 9.5(=197) 0.000 
PAS at posttreatment 7.7 ± 8.3 (n=50) 6.3 ± 6.9 (n=114) 0.269 
FQA at posttreatment 8.6± 9.5 (n=55) 6.3 ± 7.5 (n=126) 0.090 
MADRS at posttreatment 8.1 ± 6.4 (n=54) 5.1 ± 5.6 (n=121) 0.002 
SDS at posttreatment 41.4 ± 11.5 (n=55) 35.7 ± 9.5 (n=126) 0.001 
 
 
Table 3 presents the mean FQ- AGO and MADRS post- treatment scores of the 3 
groups divided according to their MADRS – score on depression severity. 
There was a significant effect of treatment on outcome measures [F(3, 248) = 236.9, 
p < .001]. Separate univariate ANOVA’s on the FQ-AGO, PAS and MADRS also 
revealed significant treatment effects [F(1, 250) = 431.8, p < .001, F(1, 250) = 597.9, p 
< .001 and F(1, 250) = 181.9, p < .001, respectively]. Manualized behavioral therapy, 
as expected, strongly reduced the intensity of symptoms as evidenced by a 
significant reduction on the FQ-AGO and PAS scores. Interestingly, manualized 
behavioral therapy specifically focused on PDA (and not on MD) also significantly 
reduced depressive symptoms. 
The impact of depressive symptoms on treatment effect can be seen in figures 1 
and 2. There was a significant effect of depressive symptoms on the FQ-AGO and 
PAS change scores [F(2, 404) = 2.793, p = .026]. Separate univariate ANOVA’s 
revealed a significant effect of depressive symptoms on PAS change scores [F(2, 
202)=495.9, p = .011] respectively] but not on FQ-AGO change scores [F(2, 
202)=431.8, p = .096]. The duration of illness (years PDA) and the use of an 
antidepressant during treatment as covariates did not significantly influence the 
effect of depression on panic measures change scores. Parameter estimates reveal 
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that compared to individuals with symptoms absent (MADRS: 0-6) patients with mild 
depression (MADRS: 7-19) have larger PAS change score by 5.269 score-points (t = 
2.836, p = .005). Furthermore, patients with a moderate depression (MADRS: 19-34) 
also had a larger PAS change score by 5.805 score-points when compared to 
subjects with symptoms absent (t = 2.614, p = .01). 
 
Table 3 Sociodemographics by MD severity  
Variable MADRS 0-6  MADRS 7-19 MADRS 20-34 Significance P < 
0.05 
N=288 N=64 N=160 N=64  
Age years 38.8 (SD 11.1) 39.7 (SD 12.5) 40.2 (SD 12.8)  P<0.804 
Females % 36 32.5 32.9 p<0.881 
Duration of the PDA. 
years 
9.8 (SD 9.3)  13.3 (SD 13.3) 10.4 (SD 10.8)  P<0.087 
Antidepressant % at 
baseline 
28.1 (N = 18) 37.3 (n = 59) 51 (n = 27)  P<0.214 
Antidepressant % during 
therapy 
19.4  41.1 57.3  p<0.000 
Smoking % 23.3 45 45.5  p< 0.08 
Depressive disorder % 0 22.3 82.3  
PAS at baseline 17.0 (SD 9.1) 24.4 (SD 9.2) 30.4 (SD 9.3)  p<0.000 
PAS at posttreatment  5.5 (SD 6.0) 8.3 (SD 7.7) 10.6 (SD 9.4)  p<0.004 
FQA at baseline  15.6 (SD 11.5) 22.9 (SD 10.7) 25.5 (SD 10.5)  p<0.000 
FQA at posttreatment  4.7 (SD 6.6)  7.5 (SD 7.5) 9.5 (SD 9.3)  p<0.002 
MADRS at baseline 3.2 (SD 1.9) 12.7 (SD 3.6) 24.6 (SD 3.8)  p<0.000 
MADRS at posttreatment  3.3 (SD 3.5)  6.9 (SD 6.2) 11 (SD 8.0)  p<0.000 
 
 
Discussion  
 
The present study shows that both depressed and non-depressed PDA patients profit 
from the manualized behavioral treatment focused on the PDA. This result is in line 
with most recent studies (Allen et al., 2010; Emmrich et al., 2012) on the effects of 
comorbidity on treatment of PDA.  
Although the comorbid group had significantly higher scores on the anxiety scales 
(PAS, FQA) at baseline, there were no significant differences anymore at post-
treatment between both groups. Both groups improved significantly during therapy 
with a reduction of more than 70% on initial scores on the PAS and a reduction of 
more than 67 % on initial scores on the FQA.  
The improvement of the FQA, as a measure for end- state functioning (Telch et 
al.,1995) in both groups was also of clinical relevance; in both the depressed and 
non-depressed group the FQA score was reduced from severe agoraphobia at 
baseline to agoraphobia in remission at post-treatment. (Cox et al.,1995; 
Mavissakalian1986) 
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Figure 1. The impact of depressive symptoms on treatment: FQ-A 
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Figure 2. The impact of depressive symptoms on treatment: PAS 
Groups according to MADRS score
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The present study also confirmed that manualized behavioral treatment focusing on 
PDA also effectively reduces depressive symptomatology as measured by the 
MADRS. This is in line with previous studies (Allen et al., 2010; Rief et al., 2000). Also the 
recently published study of Emmrich et al., (2012) reports comparable findings. 
Although the depressed PDA patients still scored significantly higher at post-
treatment on the MADRS than did the non-depressed PDA patients, there was a 
significant effect of treatment on the depressive symptoms in both groups. 
The improvement of the MADRS in both groups was also of clinical relevance; in the 
depressed group the MADRS score was reduced from “moderate” depress-sion at 
baseline to “mild” at post-treatment and in the non-depressed group from “mild 
depression” at baseline to no depressive symptoms at post-treatment (Montgomery 
and Asberg, 1979). 
Our hypothesis that PDA patients with comorbid MD tend to show more severe 
symptomatology than non-depressed PDA patients at baseline, could be con-
firmed for the specific PDA rating scales (PAS and FQA). These results are per-fectly 
in line with recent studies (Allen et al., 2010; Emmrich et al., 2012). Moreover, even 
the severity of the panic disorder, measured with the PAS, in our study (depressed 
and non- depressed group) is comparable with the findings of Emmrich. 
Unfortunately, since Emmrich et al. (2012) used another instrument for agoraphobia, 
no comparison can be made regarding severity of agoraphobic avoidance. 
As could be expected, also the specific depression assessment MADRS showed 
significantly higher scores for the depressed group.  
We defined comorbidity as the simultaneous coexistence of 2 disorders accor-ding 
to full DSM – IV criteria. Investigating the prevalence of depressive disorder as a 
comorbid diagnosis, we found a point prevalence of depressive disorder of 33 % in 
our sample of PDA patients at baseline, in the sample that entered manualized 
behavioral therapy and also in those who completed treatment. This percentage 
was well within the range we expected on the basis of earlier clinical studies (Brown 
et al., 1995; Emmrich et al., 2012; Steketee et al., 2001; Tsao et al., 2005). At baseline, 
and also in the group of the ‘completers’, we found a concurrent psychiatric 
disorder in 62 % of the patients, which is also in line with previous studies (Brown and 
Barlow 1992; Brown et al., 1995). No difference was found between the group at 
baseline, the group that entered the manualized behavioral therapy and the group 
that completed the manualized behavioral therapy regarding sex, age, duration of 
PDA, comorbidity and baseline assess-ment (PAS, FQA, MADRS). There were also no 
significant differences between the ‘completers’ and the ‘non- completers’ of the 
patients entering the manualized behavioral therapy considering age, sex, duration 
of the PDA, FQA and MADRS at baseline.  
The fact that the sociodemographic and clinical characteristics at baseline were 
similar in the different ‘consecutive’ samples (e.g. at baseline, entering behavioral 
therapy and completing therapy) is of major importance as our sample was treated 
in a setting of routine clinical care. Thus, it was not specifically the most depressed or 
severely ill patients who were lost to follow- up.  
Some shortcomings of this study must be mentioned. First, as a result of liberal 
inclusion criteria, additional comorbidity next to MD, were present in our samples. 
Second, the mean MADRS score at baseline of the depressed group that entered 
manualized behavioral therapy for PDA appeared to reflect depressive disorder of 
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only moderate severity. However, previous studies showed similar findings (Emmrich 
et al., 2012). A possible explanation for this finding can be the organization of 
mental health care in the Netherlands, where severely depressed patients are first 
referred to specialized mood disorder clinics for treatment of the depression. 
Therefore, we cannot exclude the possibility that PDA patients with a severe 
depression were preferentially referred to a mood-disorders clinic. 
Third, the nature of the study design precludes follow- up analysis to explore the 
relationship of manualized behavioral therapy for panic disorder to comorbidity 
over time. Nevertheless, several studies found that positive treatment effects are 
retained or even enhanced in the follow- up period (Emmrich et al., 2012; Tsao et 
al.1998; Tsao et al., 2002; Tsao et al., 2005). 
Finally, some of the patients were taking an antidepressant. Hence, symptoms were 
still present in spite of medication. However, the analyses did not show a significant 
influence of medication use on the patterns of change of the assessments (PAS, 
FQA, MADRS).  
At the same time, one should define some of the above weak points in relation to 
the positive points of this study, among which is its naturalistic nature. Our sample is 
directly taken from day-to-day clinical practice, which is relevant for patients in the 
clinical setting. As such, the characteristics of patients in this study can be regarded 
as typical for help seeking patients with PDA in an outpatient setting. 
Furthermore, the strengths of this study include (a) a large sample size generated 
from a single center, (b) substantial statistical power to examine our hypotheses, (c) 
the use of both clinician - rated and self- report measures on panic and depressive 
symptoms, (d) carefully use of state of the art manualized behavioral therapy for 
PDA (e) diagnostic assessments conducted by independent evaluators, (f) 
categorical and dimensional examination of the effect of depression and 
depressive symptomatology on the therapy focusing on PDA. 
The current study examined in a large group of outpatients if comorbid MD has a 
negative influence on treatment outcome for manualized behavioral therapy for 
PDA. We found that although the depressed PDA group was associated with more 
severe panic disorder symptoms at baseline, the treatment response was 
comparable in the depressed versus the non-depressed PDA group. Also, the 
manualized behavioral therapy for PDA reduced the severity of co-occurring 
depressive symptoms in both groups.  
These data suggest that comorbid MD is not an obstruction to treatment response 
and successful treatment of panic disorder is associated with reductions of 
comorbid depressive symptoms. These data support the notion that it is possible to 
treat both MD and PDA at the same time without having to adapt the therapeutic 
strategy for addressing the associated depressive symptomatology.  
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Abstract 
 
This study was intended to assess the extent to which the low- expression allele of 
the serotonin transporter gene promoter predicts better response to exposure-
based behavior therapy in patients with panic disorder with agoraphobia (PDA). 
Ninety-nine patients with PDA underwent a 1-week in vivo exposure-based behavior 
therapy program and provided saliva samples to extract genomic DNA and classify 
individuals according to four allelic forms (SA, SG, LA, LG) of the 5-HTT-linked 
polymorphic region (5-HTTLPR). We determined whether the 5-HTTLPR genotype 
predicted change in avoidance behavior in PDA following treatment. After 
controlling for pre-treatment avoidance behavior, the 5-HTTLPR low-expression 
genotypes showed a more favorable response to exposure therapy two weeks 
following treatment, compared to the other patients. This study suggests a genetic 
contribution to treatment outcome following behavior therapy and implicates the 
serotonergic system in response to exposure-based treatments in PDA. 
 
Key words: Behavior therapy, exposure therapy, genetics, panic disorder, 
agoraphobia, serotonin. 
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Introduction 
 
The serotonin transporter length polymorphism (5-HTTLPR) has received much 
attention over the last years in the study of gene-environment (GxE) interactions in 
emotional disorders. Many studies, including meta-analyses, reported an interaction 
with a variety of environmental factors while others failed to find such a relationship 
(Colasanti et al., 2011; Feinn et al., 2005; Karg et al., 2011; Minelli et al., 2011; 
Pergamin-Hight et al., 2012; Schinka, 2005; Schinka et al., 2004; Serretti et al., 2006). 
An explanation for this apparent contradiction has been proposed, in that an 
interaction effect between the 5-HTTLPR and the environment is not of a general 
nature but is restricted to some specific environmental factors (Blaya et al., 2007; 
Minelli et al., 2011; Munafo et al., 2008).  
Stein et al. (2008) found in young adults a statistically significant interaction between 
5-HTTLPR genotype and levels of childhood (emotional or physical) maltreatment. 
Specifically, SS individuals with higher levels of maltreatment had significantly higher 
levels of anxiety sensitivity. Klauke et al. (2011) showed a GxE effect of more active 
5-HTT genotypes and childhood maltreatment on anxiety sensitivity. These two 
studies provide evidence of a genetic influence on anxiety sensitivity and this effect 
is modified by severity of childhood maltreatment. Further, it has also been demon- 
strated that 5-HTTLPR SS-homozygotes who experienced 2 or more separation life 
events showed a significantly higher prevalence of panic disorder compared to 
those with SL- heterozygotes or LL-homozygotes. Also, 5-HTTLPR SS-homo- zygotes 
who experienced more separation life events showed a significantly higher harm 
avoidance (Choe et al., 2013). Together, these findings are consistent with the 
notion that 5- HTTLPR operates broadly to moderate emotional response to stress. 
The issues of replication and specificity also apply to the study of the effect of 5-
HTTLPR genotype on the therapy response in psychiatric disorders. 
Considerable effort is invested in elucidating the genetic factors that determine and 
can predict the effects of pharmacological therapy for psychiatric disorders (Arias 
et al., 2003; Keers and Aitchison, 2011; Kim et al., 2006; Perna et al., 2005; Serretti et 
al., 2006; Taylor et al., 2010; Zanardi et al., 2001). Equally important but much less 
studied is the influence of genetic variation on the efficacy of psychological 
therapy. It is both of theoretical and clinical interest to identify biological markers for 
individualization of cognitive behavior therapy (CBT) associated with successful 
outcome. These studies may give us a more nuanced understanding of 
psychopathology, which in turn can enhance the ability to tailor treatments 
individually based on genetic profile, thereby increasing the effectiveness of 
psychological treatments. This way, ‘therapygenetics’, similar to pharmacogenetics 
(Keers and Aitchison, 2011), may have the potential to determine who is more likely 
to respond to which form of treatment (e.g. CBT, drugs or both).  
Currently, there is a lack of studies investigating the role of genetic variants in the 
efficacy of CBT in panic disorder with agoraphobia (PDA). Traditionally, CGT was 
considered to exert its effect via psychosocial mechanisms in contrast with 
pharmacological treatment, which was considered to act via biological 
mechanisms. However, research has clearly shown that the changes in affect, 
behavior and cognition seen after CBT have biological underpinnings and are 
accompanied by significant and disorder specific changes in brain metabolism 
(Goossens et al., 2007; Linden, 2006; Roffman et al., 2005).  
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The genetic contribution to the liability of PDA is around 30–40% (Hettema 2001). In 
the case of anxiety disorders, several studies have suggested a genetic contribution 
to treatment outcome following CBT (Bryant et al., 2010; Eley et al., 2012; Hudson et 
al., 2013; Kim et al., 2006; Lester et al., 2012; Lonsdorf et al., 2010; Reif et al., 2014). 
The study of Bryant et al. (2010), in patients with posttraumatic stress disorder (PTSD), 
showed that six months after treatment, the 5-HTTLPR low-expression genotype 
group (S or LG allele carriers) still displayed more severe PTSD-symptoms relative to 
the other patients. Eley et al. (2012) found that the type of 5-HTTLPR predicted 
response to CBT among children with anxiety disorders. Specially, children with two 
copies of the low-expressing S-allele had better symptomatic response to treatment 
at follow-up (i.e., 6 months after completion of CBT) than children with one or two 
copies of the L-allele. Lonsdorf et al. (2010) demonstrated that panic disorder 
patients with the COMT- val158met/met genotype might profit less from (exposure- 
based) CBT treatment methods as compared to patients carrying at least one val- 
allele. In this study, no association was found with the 5-HTTLPR/rs25531 genotypes. 
Kim et al. (2006) showed that the BDNF Val66Met genotype predicts response to 
cognitive behavior therapy in PTSD. Focusing on neurotrophic genes, Lester et al. 
(2012) demonstrated in a sample of 374 anxiety-disordered children, that children 
with one or more copies of the T allele of nerve growth factor (NGF rs6330) were 
significantly more likely to be free of their primary anxiety diagnosis at follow-up. No 
signifi- cant associations were observed between brain-derived neutrotrophic factor 
(BDNF rs6265) and response to psycho- logical therapy. The same group followed up 
on these 
findings, this time using a ‘risk index’ approach combining demographic and clinical 
data with genetic data (5HTTLPR and NGF rs6330) to predict outcome of CBT in a 
group of anxious children. Results showed that children scoring high on this index 
were considerably more likely to retain their primary anxiety disorder at follow-up 
(Hudson et al., 2013). In a very recent paper, Reif et al. (2014) report on the impact 
of MAOA-uVNTR on therapy response, behavioral avoidance and brain activity 
during fear conditioning in a study on CBT in PDA. The results showed that patients 
with the long MAOA risk alleles (causing higher activity of MAO- A) profit less from 
exposure- based CBT as reflected by lower response rates. During exposure to a 
standarized behavior avoidance test, high- risk patients also reported higher anxiety, 
more panic attacks and elevated heart rate. Furthermore, fMRI scanning during a 
classical fear-conditioning paradigm in a subset of these patients (n = 42) 
demonstrated that patients carrying the protective allele showed increased 
activation of the anterior cingulate cortex (ACC) upon presentation of the CS+ 
during acquisition of fear. Such activation was absent in high-risk allele carriers 
In line with our previous work on the role of the serotonin system in PDA (Colasanti et 
al., 2011; Kim et al., 2006; Schruers and Griez, 2003, 2004; Schruers et al., 2000; 
Schruers et al., 
2002) and more specifically of the 5-HTTLPR (Schruers et al., 2011), we focused on 
the role of the 5-HTTLPR. 
In the present study, we investigated the effect of variation in the 5-HTTLPR gene on 
the efficacy of a one- week intensive exposure-based therapy for agoraphobia in a 
sample of patients with PDA. In line with the study of Eley et al. (2012), we 
hypothesized that the S-allele would be associated with enhanced response to 
therapy. 
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Materials and methods 
 
Participants 
Ninety-nine patients of white European heritage who completed the 1-week in vivo 
exposure-based behavior therapy program for PDA at the Academic Anxiety 
Centre in Maastricht, an outpatient clinic in the Netherlands, participated in the 
study. Only patients with PD with agoraphobia as primary diagnosis were included. 
Exclusion criteria were being on psychotropic medication (with the exception of 
antidepressants), severe depressive disorder, suicidal intent, psychosis, substance 
abuse or cognitive impairment. Of the ninety-nine patients, 33 patients were taking 
an antidepressant and 55 patients had a concurrent psychiatric disorder; 30 
patients had depressive disorder, 5 patients dysthymic disorder, 1 patient 
adjustment disorder, 1 patient bipolar disorder, 5 patients social phobia, 20 patients 
specific phobia, 3 patients OCD, 4 patients PTSD, 2 patients GAD, 8 patients 
somatoform disorder and 2 patients an eating disorder. The study was approved by 
the local medical ethics committee and all patients gave their informed consent 
after a detailed explanation of the procedure.  
 
Procedure 
Participants were recruited from our outpatient setting. Diagnosis according to DSM 
IV criteria was made by two experienced psychiatrists via psychiatric interview, 
including the MINI (Mini International Neuropsychiatric Interview) (Sheehan et al., 
1998).  
Further clinical assessment of anxiety was performed with two scales: The Fear 
Questionnaire (FQ) is a self- rating scale that assesses phobic avoidance. It 
produces a global score (FQ-tot) and subscores for agoraphobia (FQ- AGO), blood-
injury phobia (FQ-BI) and social phobia (FQ- SOC) (Marks and Mathews, 1979). Since 
the therapy mainly focused on avoidance behavior, the FQ-AGO was chosen as 
main outcome variable. To assess overall severity of the panic symptomatology, the 
Panic and Agoraphobia Scale (PAS) was used (Bandelow et al., 1998). De PAS 
contains 13 items grouped in five subscales: ‘Panic Attacks’ (including the items 
frequency, severity and durations), ‘Agoraphobia’ (including frequency, number 
and relevance of situations), 
‘Anticipatory Anxiety’ (including frequency and severity), 
‘Disability’ (including family, social relationships and employment) and ‘Worries 
about health’ (including worries about health damage by panic attacks and 
assumption of organic disease). The observer-rated version of the PAS was used. 
Psychometric evaluation involved also the Montgom- ery-Åsberg Depression Rating 
Scale (MADRS) (Montgomery and Asberg, 1979) to assess the severity of co-morbid 
depressive symptoms. 
The 1-week intensive, exposure-based behavioral therapy program for agoraphobia 
consisted of 5 full consecutive days of therapy. The patients' days were devoted to 
exposure to several agoraphobic situations. At first, exposure was con- ducted 
under full coaching by a licensed behavioral thera- pist. Coaching was gradually 
reduced during the week. Psychometric data were gathered before 
(approximately 6 weeks) and 2 weeks after treatment. The researcher who assessed 
the measures was independent of therapy. In the period between the first 
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psychometric assessment and the start of therapy, general information was 
provided (group- wise, together with patients with other anxiety disorders) on the 
procedures at the Academic Anxiety Center. In the week immediately before the 
start of the actual exposure treatment, each patient individually received detailed 
information on the treatment, however still without any therapy exercises or 
assignments. 
 
Genetic analysis  
Saliva samples for DNA isolation were collected in Oragene DNA Collection kits 
(DNAgenotek, Ottawa, Canada). Genomic DNA was extracted using the 
AutoGenFlex DNA isolation system (Autgen, Hilliston, MA, USA) according 
manufacturer’s instructions. 
On the 5-HTTLPR locus, rs25531 is a functional variant that defines a tri-allelic 
genotype, which consists of the LA, LG and SA alleles (SG is rare). The LG and S 
alleles have similar expression levels. Phase-known HTTLPR and rs25531 were 
determined by a modification of the procedure by Wendland (2006). 
Fragment sizes and corresponding genotypes were independently scored by two 
technicians. Genotype frequencies in the total sample (n = 99) were as follows: 
LALA, 34; LALG, 7 ;LGLG, 0 ;SALA, 35 ;SALG, 4; SGLG, 0; SASA, 19; and SASG, 0.  
In the analysis, the tri- allelic 5-HTTLPR genotype was expressed according to the 
level of expression as follows: LGS, LGLG and SS as SS; LAS and LALG as LS; and LALA 
as LL. The distribution of genotypes (LL: 34,3 %, LS: 41,4 %, SS: 24,2 %) was in Hardy-
Weinberg equilibrium. At posttreatment data of all 99 patients were available. The 
bi-/tri-allelic 5-HTTLPR locus was the only genetic marker tested in this study.  
 
Statistical analyses 
To examine the impact of 5-HTTLPR genotype on response to exposure treatment, a 
two-way analysis of variance (ANOVA) with repeated measures was conducted on 
the FQ-AGO and PAS with 5-HTTLPR group (SS, SL and LL) as the between factor and 
time (pre-treatment, post-treatment) as the within-factor. Chi-square test was used 
for categorical variables (sex, co-morbidity, use of antidepressants). To compare the 
means of the non-categorical variables, a one-way ANOVA was used (age, 
duration of the PDA, FQ-AGO pre-treatment, FQ-AGO post-treatment, PAS pre-
treatment, PAS post-treatment, MADRS pre-treatment, MADRS post-treatment). The 
results are presented as means ± standard deviations and significance levels were 
set at p<0.05 (two-tailed). 
 
Results 
 
Demographic and clinical Data 
There were no significant differences between the three groups in terms of sex, age, 
duration of the PDA. There were also no significant differences in antidepressant use 
and/nor comorbidity (table 1). 
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Treatment response 
Table 2 presents the mean avoidance behavior severity (FQ-AGO) pre-treatment 
and post-treatment, and the impact of5-HTTLPR genotype on treatment response 
can be seen in fig. 1.  
There was a significant effect of treatment as measured by the FQ-AGO and PAS 
[F(1, 96)=347.6, p<0.001 and F(1, 84)=239.3, p<0.001, respectively]. Intensive 
exposure-based behavior therapy, as expected, strongly reduced the intensity of 
symptoms as evidenced by a significant reduction on the FQ-AGO and PAS scores.  
There was also a significant treatment X genotype interaction effect as measured 
by the FQ-AGO and PAS [F(2, 96)=4.0, p=0.02 and F(2, 84)=3.3, p=0.041; 
respectively]. Post hoc comparison shows that after therapy patients with the LL 
genotype have a smaller FQ-AGO score reduction when compared with patients 
with the SS genotype and the SL genotype [t(56)=-2.724, p=0.009 and t(68.2)=-2.006, 
p=0.049; respectively] and a smaller PAS score reduction when compared with the 
SL genotype, but no difference when compared with the SS genotype [t(65)=-2.167, 
p=0.034 and t(50)=-.013, p=0.98; respectively].  
 
 
 
Fig. 1. The impact of 5-HTTLPR genotype on treatment response. FQ–AGO: Fear 
Questionnaire-agoraphobia subscale 
 
Discussion 
 
Intensive exposure-based behavior therapy strongly reduced the intensity of panic 
and avoidance (or PDA) symptoms as evidenced by a significant reduction on the 
FQ-AGO and PAS scores. Further, there was also a significant treatment X genotype 
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interaction effect. Patients with the LL genotype had a smaller FQ-AGO score 
reduction when compared with patients with the SS genotype and the SL genotype 
and a smaller PAS score reduction when compared with the SL genotype. As 
hypothesized, these findings show that the efficacy of exposure-based behavior 
therapy depends on the 5-HTTLPR polymorphism where PDA patients with the SS/SL 
genotype profit more as compared to patients with the LL genotype.  
 
 
Table 1. Patient characteristics PDA. Panic disorder with Agoraphobia. 
 SS  
(n = 24) 
SL  
(n = 41) 
LL  
(n = 34) 
 
Male 5 (21%) 8 (19.5%) 13 (38%)  
X2 = 3.847; df = 2; p = 0.146 
Female 19 (79%) 33 (80.5%) 21 (62%) 
Age (y) 36.8±10.3 38.8±11.9 41.1±13.7 F = 0.605; df = 2; p = 0.548 
PDA duration (y) 10.9±9.2 12.1±12.0 12.7±11.6 F = 2.896; df = 2; p = 0.060 
Antidepressant use 6 9 10 X2 = 0.131; df = 2; p = 0.936 
Comorbid 
depression 
8 12 10 X2 = 0.138; df = 2; p = 0.933 
Comorbid specific 
phobia 
6 8 6 X2 = 0.493; df = 2; p = 0.782 
 
 
Table 2. Treatment response by 5-HTTLPR genotype. FQ-AGO: Fear Questionnaire-
Agoraphobia Scale. MADRS: Montgomery-Asberg Depression Rating Scale. PAS: 
Panic and Agoraphobia Scale. 
 SS  SL  LL  
 Pre Post Pre Post Pre Post 
FQ-AGO 28.8±5.5 7.6±5.3 27.4±7.8 8.2±6.5 26.7±7.8 12.2±10.5 
PAS 26.6± 7.7 11.0± 8.4 29.2±7.6 7.9± 7.1 29.9 ±7.7 14.4± 8.7 
MADRS 12.9 ±7.3 8.1 ± 7.3 13.2± 7.2 9.0±7.7 14. 9±98.7 9.0± 6.9 
 
 
Previous studies have looked into the relationship between the 5-HTTLPR and the 
success of different forms of cognitive behavioral therapy, showing mixed results. In 
one study, the SS-genotype was associated with a better treatment outcome (Eley 
et al., 2012). Subjects in this study were 584 children aged 6–13 years who received 
CBT for varied anxiety disorders. Successful treatment response was defined as the 
absence of an anxiety disorder at the end of the study. Twenty percent more 
children with the SS 5- HTTLPR genotype showed a favorable treatment response at 
6-month follow-up, but not directly at post-treatment. In a study with only panic 
disorder patients (n = 69), the S/LG- allele of the 5-HTTLPR genotype (both bi-and tri-
allelic) was associated with higher symptom severity prior to CBT but no association 
was found between genotype and the outcome of CBT (Lonsdorf et al., 2010). This 
lack of association between genotype and treatment success might be related to 
several issues. For instance the used outcome measure (HADS, Hospital Anxiety and 
Depression Scale) does not specifically measure panic symptoms or avoidance 
behavior due to panic attacks. Further, the use of two different CBT interventions 
(regular group and internet-based) could lead to a differential efficacy and 
therefore lack of power. In a study of 384 children with a primary anxiety disorder, 
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significant genetic, demographic and clinical predictors of outcome following CBT 
were identified (Hudson 2013). In predicting treatment outcome, six variables had a 
mini- mum mean beta value of 0.5 (5HTTLPR, NGF rs6330, gender, primary anxiety 
severity, comorbid mood disorder and comorbid externalizing disorder). A risk index 
constructed from these variables had moderate a predictive ability in this study. 
Children scoring high on this index were approxi- mately three times as likely to 
retain their primary anxiety disorder at follow-up as compared with low scoring 
children children. These results indicate that while in themselves functional 
polymorphisms appear to be insufficient to pre- dict therapy outcome, this does 
become feasible when combining them with clinical data. In the study of posttrau- 
matic stress disorder, the effect of the 5-HTTLPR on the success of CBT (n = 45) has 
been examined as well, but here the L allele was associated with a more favorable 
outcome (Bryant et al., 2010). Fewer patients homozygous for the L-allele, 
compared to the S-allele carriers, met diagnostic criteria for PTSD at follow-up. It is 
noteworthy that immediately at the end of therapy, after 8 weeks of exposure-
based CBT, no significant difference was found between genotypes. The difference 
only became apparent at 6-month follow-up, when the S-carriers seemed to 
relapse slightly whereas the L-carriers maintained their therapeutic effect. These 
genotype effects seen months after the delivery of CBT in the studies of Eley and 
Bryant suggests that other factors, apart from or only indirectly related to CBT, might 
be at play. The 5-HTTLPR appears to influence the success in which people cope 
with stressful life-events in general (Caspi et al., 2010; Caspi and Moffitt,2006; Caspi 
et al., 2003; Uher, 2009). It cannot be excluded that the effects of these studies are 
due to a general effect of the 5-HTTLPR on stress-sensitivity and coping, indirectly 
reflected in the improvement scores. The duration of the treatment described in the 
present study was only one week and the effects were measured shortly after. It is 
therefore more likely that these effects were due to the therapeutic intervention 
itself. 
It is important to emphasize that the treatment in the present study consisted almost 
exclusively of exposure in vivo. This is different from the higher mentioned studies that 
employed a variety of techniques, albeit under the common denominator of CBT: 
imaginary exposure, exposure in vivo, cognitive restructuring, delivered via 
individual therapy, group therapy or Internet based therapy. As mentioned before, 
different aspects of therapy rely on different psychological processes and therefore 
likely also on differ- ent brain processes. The more varied psychological techni- ques 
are employed in a therapy, the more difficult it becomes to attribute the effect of 
genetic variation on the overall success of therapy to a particular technique and its 
supposed underlying biological mechanism. Exposure in vivo can be considered a 
form of extinction learning. Unfortunately however, direct experimental evidence 
(with extinction rate as outcome measure) for the effect of the 5-HTTLPR on 
extinction learning in humans is currently lacking (Lonsdorf and Kalisch, 2011; 
Lonsdorf et al., 2009). A separate line of gene-environment interaction 
research, that may partially reconcile these contrasting findings, provides direct 
support for the view that the low- expression form of the 5-HTTLPR gene is best 
regarded as a plasticity gene rather than a vulnerability gene (Belsky et al., 2009a; 
Belsky and Pluess, 2009b; Fox et al., 2011; Homberg and Lesch, 2011). In these 
studies, the S-allele increases sensitivity to the environment in a more general way; 
adverse environments lead to negative outcomes, and therefore may increase risk 
for psychopathology, while positive and supportive environments may ameliorate 
risk (Belsky et al., 2009a; Belsky and Pluess, 2009b; Uher, 2008). The environment 
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shapes the outcome of these fundamen- tally neutral common genetic factors 
(Uher, 2009) and it seems that there is a cost to the ‘protective’ L-allele since it may 
render less ability to maximize the potential of favorable situations (Belsky et al., 
2009a; Homberg and Lesch, 2011; Uher, 2009). Several studies are compatible with 
the view that the 5-HTTLPR gene reflects environ- mental sensitivity. Fox et al. (2011) 
show that healthy individuals with the S-allele develop a stronger bias for both 
negative and positive affective pictures relative to those with L-allele of the 5-HTTLPR 
gene. Roiser et al. (2007) shows that in several studies the S-allele of the 5-HTTLPR 
gene is associated with improved cognitive functions. 
Several limitations to our study need to be mentioned. First, although the sample size 
is among the largest of the studies into this subject focusing on a single anxiety 
disorder, it is still modest for a genetic study. This made for insufficient power to 
investigate other polymorphisms of interest that certainly exist. Especially the 
COMTVal158Met polymorphism, which is associated with poorer extinction learning 
as well as with CBT success in PDA, is worth investigating in future treatment studies 
(Lonsdorf and Kalisch, 2011). Second, some of the patients were taking an 
antidepressant. Hence, symptoms were still present in spite of medication. It is 
possible that there may be an overrepresentation of patients who did not respond 
well to the pharmacological treatment. However, no differences in medication 
status between the genotype groups were observed. Also, an effect of medication 
is rather unlikely given that patients were on a constant dosage for 2 months prior to 
inclusion. An additional effect of the medication on the PDA-symptoms after such a 
long period of time is not to be expected, but can never be ruled out (Bakker et al 
2005). We therefore cannot completely exclude the possibility that medication 
status may have affected treatment outcome. Third, the outcome was measured 
shortly (2 weeks) after therapy. This design does not allow for evaluation of 
intermediate/long-term effects, as have been demonstrated in other therapy-
genetic studies (Lonsdorf et al., 2010). 
Our findings show that the 5-HTTLPR polymorphism may play a role in the response to 
exposure-based behavioral treatment in PDA. Overall, the 1-week intensive 
behavioral treatment dramatically reduced the intensity of agoraphobic symptoms 
in all patients. However, after therapy, those carrying the S-allele had agoraphobia 
scores compatible with complete remission, while L-carriers ended up with scores still 
compatible with mild agoraphobia (Mavissakalian, 1986; Roy-Byrne et al., 2005). 
These data support previous findings, indicating that genetic profiling might have a 
future role in identifying patients beforehand that require longer or more intensive 
psychological treatment. 
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Chapter eight 
 
 
 
 
 
 
 
 
General discussion 
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The aim in this thesis was to establish and understand the impact of gene and 
environmental factors on panic disorder while at the same time further our 
knowledge about factors that influence the effect of behavioral cognitive-therapy 
(CBT) in panic disorder (PD). To achieve this, first, CO2 inhalations were used as a 
model to provoke panic and smoking as a technique to enhance this panic 
provocation. Next, CBT was employed as a behavioral technique to gain insight in 
factors that determine the effect of psychological therapy in PD. Third, genetic 
techniques were used to explore a key neurotransmitter system and its relationship 
to PD symptom severity. The findings are discussed here and some concluding 
remarks are made. 
 
Factors that influence panic 
 
After experiencing a panic attack many PD patients start smoking more in an effort 
to avoid panic attacks (‘self medication’). Smoking, however, seems to exacerbate 
rather than reduce panic symptoms. Since there is evidence supporting the idea 
that smoking can be anxiogenic but also anxiolytic, the question remains if ‘smoking 
leads to panic’ or ‘panic leads to smoking’ (chapter 1). In chapter 3 and chapter 4 
we investigated the role of smoking in panic. Chapter 3 describes an experimental 
study designed to test the ‘panic’ effects of smoking on the 35% CO2 challenge. 
Ninety-two patients (46 smokers and 46 non-smokers) with panic disorder and 
agoraphobia (PDA) were evaluated. The results show that PD smokers had a larger 
response to CO2 when compared to PD non-smokers. While baseline measures 
were similar in both groups, PD smokers reacted with more panic symptoms to the 
challenge. Fear scores showed the same effect, however without reaching 
statistical significance. In chapter 4, the literature regarding the comorbidity 
between cigarette smoking/nicotine dependence and panic (either panic attacks 
or panic disorder with or without agoraphobia) was surveyed. The aim was to 
achieve a broader perspective on the relationship between panic and cigarette 
smoking and to identify the possible underlying etiologic mechanisms. Twenty-four 
of the 61 studies screened met inclusion criteria. First, an overview of studies 
estimating the prevalence of the co-occurrence of cigarette smoking/nicotine 
dependence and panic attacks/panic disorder with or without agoraphobia was 
presented. Second, an overview of studies that examined the 3 causal models (from 
panic to smoking, from smoking to panic, and shared vulnerability) in turn was 
offered. Finally, experimental studies using laboratory panic provocation procedures 
were considered. These studies addressed the underlying mechanisms of the panic/ 
smoking link. Panic and cigarette smoking each appeared to have the capacity to 
serve as a causal factor in the development of the other. The bulk of the literature 
also supports a link between smoking and panic. The pathogenetic explanations of 
this co-occurrence referred mainly to 3 hypotheses. According to a moderational 
model, neuroticism is a third factor linking smoking to panic, as it moderates smoking 
frequency in subjects with a lifetime history of panic. According to a pathoplastic 
model of dysfunction, smoking acts as a vulnerability factor that modifies the 
expression of panic disorder by exacerbating affective disturbances and negative 
health processes. Finally, in line with the false suffocation alarm theory, smoking, by 
means of increasing the risk of lung disease or impacting the carotid body, may 
reduce the threshold to suffocation signals and indirectly increase the risk of panic. 
The first 2 hypotheses have been supported by several studies. A few studies found a 
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unidirectional relationship going from smoking to panic. Only one study showed a 
bidirectional relationship between smoking and panic. In experimental work almost 
all studies have found that cigarette smoking increases fear reactivity to a biological 
challenge, both in panic disorder patients as in healthy volunteers. In studies 
evaluating patients with nicotine dependence, it was found that the more severe 
the level of nicotine dependence, the higher the risk of comorbidity with panic.  
 
Previous literature has clearly shown the large extent of a comorbid depressive 
disorder in PD patients. Literature also suggests that a concurrent depressive disorder 
may also influence the severity of the panic symptoms. A large body of evidence 
has documented that the effects of cognitive behavioral therapy (CBT) for the 
treatment of panic disorder are robust and durable. With regard to CBT, some 
evidence suggests that a concurrent depressive disorder influences the treatment 
outcome for manualized behavioral therapy for PDA. Furthermore, CBT focussing on 
the panic disorder, may also improve the concurrent depressive symptoms (chapter 
1). Chapter 6 describes a study examining the relationship of comorbid depression 
on treatment outcome for manualized behavioral therapy for PDA in a large group 
of outpatients. It was found that both depressed and non-depressed PDA patients 
profit from CBT focused on the PDA, which is in line with most recent studies. 
Although the comorbidity group had significantly higher scores on the anxiety scales 
(PAS, FQA) at baseline, there were no significant differences at post-treatment 
between groups. Both groups improved significantly during therapy with a reduction 
of more than 70% on initial scores on the PAS and a reduction of more than 67% on 
initial scores on the FQA. In the depressed group the FQA score was reduced from 
severe agoraphobia at baseline to agoraphobia in remission at post-treatment and 
in the non-depressed group from severe agoraphobia at baseline to agoraphobia 
in remission at post-treatment. The present study also confirmed that manualized 
behavioral treatment focusing on PDA also effectively reduces depressive 
symptomatology as measured by the MADRS, which is also in line with previous 
studies. Although the depressed PDA patients still scored significantly higher at post-
treatment on the MADRS than did the non-depressed PDA patients, there was a 
significant effect of treatment on the depressive symptoms in both groups.  
 
Although the extent of the contribution of genetics versus environmental factors on 
PD is still not clearly defined, we cannot rule out an important role of genetics in PD. 
Some studies suggest that genes also play a role in treatment outcome following 
behavior therapy (chapter 1). Chapter 5 shows a relationship between the 5-HTT-
linked polymorphic region (5-HTTLPR) genotype and the response to exposure-
based behavior therapy in patients with PDA. Ninety-nine patients with PDA 
underwent a 1-week in-vivo exposure-based behavior therapy program and were 
classified according to their 5-HTTLPR genotype. It was found that intensive 
exposure-based therapy reduced measures of panic and avoidance (or PDA) 
symptoms as evidenced by a significant reduction on the FQ-AGO and PAS scores. 
Furthermore, there was a significant treatment by genotype interaction effect. 
Patients with the LL-genotype had smaller FQ-AGO reductions when compared with 
patients with the SS-genotype and the SL-genotype and smaller PAS reductions 
when compared with the SL-genotype.  
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Clinical relevance 
 
Since the work in this thesis has established that cigarette smoking has the tendency 
to promote panic itself (chapter 3 and chapter 4), quitting smoking might prevent 
relapse in panic symptoms. Therefore, smoking cessation interventions should be 
added to the general treatment plan of the smoking PD patient.  
Based on the current literature, CBT is the first choice in the treatment for panic 
disorder and exposure in vivo is indicated if agoraphobia is present. Many studies 
show that ‘short-term CBT’, this is 12 weekly sessions of CBT, is effective in treating PD 
(chapter 1). In an effort to think about cost-effectiveness of treatments and also to 
make CBT available to more patients, offering CGT in a more high-density format 
could be a solution. The question is if a 12-week CBT program is necessary to treat 
PD successfully or can this program be intensified. In chapter 5, the results of a study 
that tested the efficacy of an intensive 1-week behavioral therapy program 
focusing on agoraphobia for PDA patients are is reported. The main outcome 
measure was the agoraphobia score of the Fear Questionnaire (FQ-AGO). The 
outcomes on the FQ- AGO after a 1-week intensive therapy (96 patients) and a 
twice-weekly therapy (98 patients) were compared. It was found that agoraphobia 
improved significantly in both groups, 1 week and 3 months after therapy, 
respectively. This study shows that a 1-week CBT program for PD patients with severe 
agoraphobia was as successful as the classical 12 ‘weekly’ CBT format, allowing PD 
patients to return faster to work and to recapture their daily activities. The more 
rapid reduction of symptoms is not only an advantage for the individual, but it also 
has economic benefits for the community. Since modified CBT, like intensified 
therapy, proves to be as effective as the standard therapies, it can be offered to a 
broader population of patients with panic disorder. Intensified CBT would for 
example be useful for patients who cannot attend the standard 12 weekly sessions 
because of practical problems such as lack of child care, transportation, financial 
resources or scheduling conflicts with working hours. 
Since a comorbid depressive disorder in PD does not appear to affect the outcome 
of CBT focusing on PD negatively and moreover, the depressive symptomatology is 
reduced ‘spontaneously’ (chapter 6), it seems possible to treat both psychiatric 
disorders at the same time without modifying the therapeutic plan of treating PD. 
Treating the panic disorder seems to have beneficial effects on the depressive 
disorder, and therefore it would be more cost effective to treat the principal 
disorder, PD, instead of to spend extra time and means to treat each disorder 
separately. The high co- occurrence of these two mental disorders, and the 
knowledge that panic disorder usually precedes the onset of the depressive 
disorder, makes that PD patients should be carefully checked for the presence of a 
depressive disorder. However, it is recommendable to assess both disorders 
consistently disregarding the initial reason for consultation. Since our sample is 
directly derived from an outpatient setting, patients on medication and patients 
with all kind of comorbidity were included. Therefore, the characteristics of the 
patients can be considered as typical for PD patients in an outpatient setting. The 
naturalistic nature of the study ensures that our results are relevant for daily clinical 
practice. In chapter 5 we showed that PD patients carrying the S- allele of the 5-
HTTLPR polymorphism had a better response to the 1-week intensive behavioral 
treatment CBT program than S- allele carriers.  
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When editing the individualized therapy program of the individual with PD at the 
start of the treatment, genetic profiling could be considered since L- allele carriers 
might demand a longer or more intensive treatment. 
 
Future research 
 
The finding that cigarette smoking has the tendency to promote panic itself is 
consistent with previous research that cigarette smoking appears to be a causal link 
in the development of PD. Smoking also seems to precede the onset of panic, 
however reviewing the literature, the relation to time is still under debate. The 
etiopathogenetic explanations of this co-occurrence are also still being discussed. 
The following studies can maybe shed light into this temporal pattern and the 
underlying mechanisms: (1) epidemiologic studies involving new samples, (2) 
epidemiologic and clinical studies with attention for the gender, (3) clinical studies 
comparing the link between smoking and other anxiety disorders with the 
relationship between smoking and panic (4) experimental studies carried out in 
sovereign labs and (5) replication of research focusing on mutual vulnerability. 
Furthermore, trials illuminating the link between certain lifestyles, such as regular 
exercise, and panic disorder could contribute to optimizing treatment of PD. 
Smoking however, should be considered as a substance use disorder rather than a 
lifestyle or habit, as a standardized use of the diagnosis of nicotine dependence will 
benefit the diagnostic evaluation and will be helpful in comparing studies.  
Since cost-effectiveness of treatment is a major topic in health care, the finding that 
a 1-week CBT program for PD patients with severe agoraphobia was as successful 
as the classical 12 ‘weekly’ CBT format, is important. Further examining the 
possibilities to shorten the duration of therapy is crucial. 
Clinical trials investigating the effect of high-density therapy, which means several 
hours of therapy within a few days, and also other modified forms of CBT (for 
example internet-based CBT) are needed since they also increase the accessibility 
of CBT. One of the limitations in comparing studies examining the effectiveness of 
CBT, which consist of multiple aspects, is the difficulty to determine which 
components are responsible for producing favorable outcomes. Studies 
disentangling CBT in his different components would be very valuable since 
‘straight- forwarded’ interventions can lead to a faster reduction of the panic 
symptoms. 
Since the treatment for panic disorder is delivered in the ‘real world’, and 
concurrent mental disorders are the rule and not the exception, studies examining 
the effectiveness of different approaches for PD, should include comorbidity in an 
attempt to complete the findings of rigorously controlled efficacy trials. Only if the 
characteristics of the participants are clear, this can lead to defining the optimal 
pathways and approaches in treating PD across the variety of settings (e.g. primary 
care, tertiary settings)  
To date, little research is available about the genetic factors that can predict 
response on CBT in PD. Studies aiming to identify genes that are associated with 
response to CBT, or other therapies, could lead to a more tailored approach and in 
time maybe to personalized medicine. More knowledge in this field would also help 
to identify the individuals more at risk for the disorder. To gain more insight in the 
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complex, non-Mendelian, traits of PD, association studies, using candidate genes, 
are promising.  
Defining genes that increase susceptibility to panic disorder and delineating genes 
that interact with known environmental risk factors such as smoking, could also help 
in optimizing and developing current and new treatments in PD.  
 
In general, studies defining the characteristics that can predict positive response to 
a known psychological or pharmacological PD treatment are needed. These 
‘predictors’ could help the psychiatrist in choosing the most effective treatment for 
that specific individual with PD.  
Since 70% of the (succesfully) treated PD patients keep on having some degree of 
panic symptoms over the course of several years, more research is needed to 
evaluate long-term effectiveness and to individualize and optimize relapse 
prevention strategies. A clear definition of relapse and remission is needed. Most 
studies address only short- term outcomes, leaving many questions concerning 
relapse unanswered. Studies including follow- up periods of several years are 
needed in order to get more insight into factors and treatments that can help to 
maintain remission. 
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Chapter nine 
 
 
 
 
 
 
 
 
Valorization 
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Societal need 
 
The twelve month prevalence of PD is estimated around 1% and the lifetime 
prevalence rates range from 1,5 to 4,7 % (Mendlowiz and Stein, 2000; Norton et al., 
2008; Pane – Farre et al., 2014). As described elsewhere in this thesis (see the 
introduction), panic disorder can lead to substantial human suffering and 
dysfunction (e.g. Wittchen et al., 1998; Alonso et al., 2004a; Kessler et al., 2006) and 
also to a high economic strain on society (Katon et al., 2002; Zaubler and Katon, 
1998). If not treated, there is a real chance that panic disorder becomes a chronic, 
very disabling disease.  
Data regarding the cost of panic disorder are particularly relevant since panic 
disorder is frequently left untreated; at least half the patients with panic disorder do 
not get help (Wang et al., 2005; Leon et al., 1995), but can potentially be treated 
successfully (van Balkom et al., 1997; Bakker et al., 2002). By reducing both medical 
(also non-psychiatric) expenses and production losses (Magruder and Calderone, 
2000), treating panic disorder more efficiently is likely economically worthwhile. 
Like in every disorder or illness, the costs associated with panic disorder can be 
divided into direct medical costs, direct non-medical costs and indirect costs 
associated with the specific morbidity. 
Direct medical costs consist of treatment costs generated by a wide scope of 
health services including the prescription of drugs. Direct non-medical costs consist 
of expenses that arise when people travel to health service providers (Oostenbrink 
et al., 2004). Indirect non-medical costs caused by panic disorder consist of costs 
due to the loss of paid labor and decreased functioning in personal life.  
 
The nature of the symptoms of panic disorder, often accompanied with avoidance 
behavior (Weissman et al., 1997), is inherently connected with higher costs; a lot of 
physical symptoms leading to the wrong diagnosis, often followed by referral to the 
wrong service (Harvison et al., 2004), excess impairment (Kessler et al., 2005; Alonso 
et al., 2004a; Kouzis and Eaton, 2000), unfavorable natural course (Eaton et al., 1998; 
Robins et al., 1991; Wittchen, 1988). Moreover, these cost increasing factors often 
lead to absenteeism from work and work cutback days (Alonso et al, 2004a). 
Further, comorbidity of panic disorder with other mental disorders (Alonso et al., 
2004b) is frequent and adds further to the costs. As panic disorder affects many 
people (Kessler et al., 2005), the cost for the community is substantial.  
 
Cost of illness studies performed in the Netherlands, have done an attempt to 
calculate the economic impact of panic disorder on society (Batelaan et al., 2007; 
Smit et al., 2006) and to compare the economic cost of panic disorder with other 
mental disorders. These data were derived from a prospective psychiatric 
epidemiologic survey that was conducted in the adult general population of the 
Netherlands (Bijl et al., 1998).  
 
Smit et al. (2006) showed that the estimated annual costs per patient (‘per- capita 
costs’) suffering from panic disorder (with or without agoraphobia) were €13,894. At 
least three quarters of costs were due to loss of production whereas direct non- 
medical costs only accounted for a limited fraction (less then 10%) of total costs. The 
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study also showed that panic disorder generated €226 million costs per one million 
inhabitants annually (‘the costs on societal level’). At population level, the costs 
generated by panic disorder were both in the same range of costs generated by 
major depressive disorder and dysthymia combined and also in the same range of 
costs generated by generalized anxiety disorder, social phobia and simple phobia 
combined.  
As expected, comorbidity increased costs (Jacobi et al., 2004; Knerer et al., 2005) 
but since only one fourth of the annual per capita costs was attributable to the 
concurrent mental disorder, this effect was moderate.  
It is important to realize that this is a conservative cost estimation since the span of 
the study of Batelaan et al. (2007) was narrowed to the year 2003. The costs over a 
longer time, such as mortality costs and costs generated by secondary disorders, 
were therefore not included. Previous studies however suggest that these costs in 
the long run might be substantial in panic disorder (Goodwin et al., 2004; Greenberg 
et al., 1999). Since service use and work loss days were assessed retrospective by 
self-reports, and decreased productivity while at work (‘work cut-back’) can be 
substantial (Greenberg et al., 1999; Kessler and Frank, 1997; Lim et al., 2000) but 
could not be measured for obvious reasons, there is a real chance that these 
outcomes are also an underestimation. A considerable cost that is also not 
accounted for in this estimation are the frequent visits to various (non-psychiatric) 
medical specialists and emergency departments (Leon et al., 1997; Rees et al., 
1998; Greenberg et al.,1999).  
Since PD is associated with multiple physical symptoms and the intensity of these 
symptoms is often mistaken for a life-threatening physical illness such as a heart 
attack, PD patients often visit emergency rooms where they often receive extensive 
and very costly medical check-ups (Katon et al., 2002; Zaubler and Katon,1998).  
 
Although the total medical cost will increase following adequate treatment 
(Andrews et al., 2004; Salvador-Carulla et al.,1995), the production ‘gain’ after 
treatment will reduce the overall societal costs and will improve the quality of life of 
the individual significantly (Salvador-Carulla et al., 1995). So, given the present low 
treatment rate for panic disorder (Wang et al., 2005), increased treatment 
coverage would lead to a substantial reduction of the societal costs. 
 
On the basis of these data, we can conclude that both the costs per individual as 
the societal costs of panic are substantial, that the loss of production seems the 
biggest part of the costs and that panic disorder is one of the most costly common 
mental disorders. Consequently, panic disorder should be regarded as a public 
health problem with great economic consequences.  
In a time that cost- effectiveness is the ‘keyword’ in health care, further studies 
focusing on health economics, both on individual and on societal level, are 
warranted. Especially studies based on the general population are important since 
they have ‘access’ to the costs of all panic patients regardless of whether they 
received treatment. If we would only focus on treatment samples (e.g. Rees et al., 
1998), we would overlook a substantial part of the costs since at least half the 
subjects with panic do not receive help (Wang et al., 2005; Leon et al., 1997). 
Although these patients generate fewer costs in health care, they may generate 
substantial costs due to absenteeism from work. The company doctor is therefore a 
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key player in the early detection of patients with a panic disorder. Also, map-ping 
the medical costs associated with the visits to numerous (non-psychiatric) medical 
specialists and emergency departments is a necessity. Further studies are also 
needed to verify whether improved ‘patient-finding’ followed by providing 
treatment according to the evidence-based guidelines of panic disorder, would 
indeed reduce the economic costs to society.  
 
Although the resources are limited and efforts to limit costs are needed, the 
constant pressure to treat patients ‘‘shorter and quicker’ in order to increase the 
‘production’, is nowadays enormous in mental health. If studies show that a specific 
therapy can be limited in time, for instance if intensified, this does not automatically 
mean that every therapist is capable of performing this therapy; know-how and 
expertise are essential. Constantly cutting on costs in mental health has its limits 
since it threatens working according to the evidence-based guidelines and 
therefore quality of care. 
 
Target groups 
 
First of all, panic patients should benefit from the results of this thesis. Smoking 
cessation might be a strategy in the prevention of, or preventing relapse in, panic 
symptoms. The duration of cognitive behavioral therapy focusing on panic disorder 
with agoraphobia (PDA), could be shortened, if intensified, and this could have 
several benefits for the patients; easier access to therapy, a more rapid reduction of 
symptoms and thus a more rapid return to work and resumption of daily activities. 
PDA patients with a comorbid major depression can be treated for the depression 
and PDA at the same clinic. 
General practitioners, company doctors, (non–psychiatric) medical specialists (such 
as the cardiologist, pulmonologist and emergency doctor) but also psychiatrists and 
mental health workers in general, should be informed about the high prevalence 
and the heterogeneous symptomatology of PD and be aware of their important 
role in especially the early detection of the PD patient. Since the public authorities 
decide how to divide the resources in mental health, they should be informed 
about the (economical) impact of PD on society.  
 
Activities/ Products/ Innovation 
 
Informing the general public about the symptoms and extent of PD is essential. 
Many panic patients are embarrassed, feel ‘weird’ and different, and therefore wait 
many years before telling the general practitioner about their complaints. Involving 
patient organizations can help to educate the general population. Personal stories 
in popular media like women’s magazines often help patients to make the first step. 
Publishing in more general medical journals (also Dutch papers) and lectures for 
general practitioners and company doctors, will lead to more knowledge about PD. 
Working closer together with the medical (non- psychiatric) specialists in the general 
hospitals can prevent medical shopping as they play a key role in the (early) 
detection of PD.  
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The application of our results in the Academic Anxiety Center, is the first step in an 
effort to replicate our results and extend our knowledge of PD; introducing a 
smoking cessation program as part of treatment strategy in PD, further explora-tion 
of strategies to shorten the duration of therapies focusing on PD, treating PD 
patients with comorbid major depression the same as PD patients with no 
comorbidity and systematically collecting DNA samples from PD patients in an 
attempt to develop in time a more personalized treatment protocol according to 
the patient’s genetic profile.  
 
Since the exact underlying pathophysiology of panic remains largely unknown, 
more knowledge on the genetic determinants and the environmental factors that 
play a role in panic is necessary. The use of the 35% CO2 challenge can be 
considered as a good experimental model for panic and can therefore be used in 
order to get more insight in the underlying pathophysiology of panic disorder with 
the aim of earlier detection of PD. Using CO2 challenges in translational research, 
imaging, and genetic research, will extend our knowledge on PD and maybe even 
lead to prevention strategies of PD. CO2 challenges are already used in treatment 
of PD as interoceptive exposure and therefore can help to develop better 
treatment strategies.  
 
Collaboration with other research groups, also international, is since many years an 
important topic at the Academic Anxiety Centre. Also teaching medical (non- 
psychiatrists and psychiatrists) specialists from other hospitals to perform CO2- 
challenges is part of spreading the know-how of PD. In order to develop better and 
more adjusted equipment to perform CO2 challenges, and to make the equipment 
available to other research groups but also clinical settings, there has been already 
collaboration with “Maastricht Instruments”.  
 
Employing acquired skills within network 
 
Writing this thesis, I learned the steps of research; formulating a hypothesis, writing 
the protocol for a study to substantiate such a hypothesis, organizing carefully the 
practical matters, collecting data, ‘looking’ at data to understand what they say, 
making statistical analyses and writing papers. Furthermore, I learned the techniques 
of the 35% CO2 - challenge. The combination of clinical work, management tasks, 
teaching and performing research activities created the opportunity for 
collaboration at several levels between clinical and research groups. 
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SUMMARY 
 
The introduction in chapter 1 illustrates the daily life of a patient with panic disorder 
(PD). The case report includes the clinical presentation, diagnostic evaluation, 
psychometric evaluation, the use of the CO2 challenge and the choice of 
treatment. Also, the diagnostic ‘tools’, the implications for the individual and society, 
the factors that have an influence on PD and the different ways to treat PD are 
described.  
 
Chapter 2 gives a general overview of the studies performed in this thesis. The aim of 
this thesis was to establish and explain the impact of gene and environmental 
factors on panic disorder. At the same time, the objective was to extend our 
knowledge about factors that have an impact on the effect of cognitive- 
behavioral therapy (CBT) in panic disorder (PD).  
 
To get more insight in the environmental factors that influence panic, CO2 
inhalations were used as a model to provoke panic and smoking as a technique to 
enhance this panic provocation. Chapter 3 describes an experimental study 
constructed to investigate the ‘panic’ effects of smoking on the 35% CO2 
challenge. While baseline measures were similar in both groups, the 46 PD smokers 
reacted with more panic symptoms to the challenge when compared to the 46 PD 
non-smokers. Fear scores showed the same effect, but without reaching statistical 
significance. These results suggest that smoking facilitates 35% CO2 acute ‘panic’ 
effects in PD patients and support the hypothesis that prior regular smoking 
increases the risk for panic attacks in PD patients. 
  
The literature regarding the comorbidity between cigarette smoking/nicotine 
dependence and panic (either panic attacks or panic disorder with or without 
agoraphobia) was reviewed in chapter 4. The intention of the review was to 
achieve a wider picture on the relationship between panic and cigarette smoking 
and to determine the potential underlying etiologic mechanisms. The studies that 
were included were divided into 3 categories; studies estimating the prevalence of 
the co-occurrence of cigarette smoking/nicotine dependence and panic 
attacks/panic disorder (with or without agoraphobia), studies that examined the 3 
causal models (from panic to smoking, from smoking to panic, and shared 
vulnerability) and experimental studies using laboratory panic provocation 
procedures and so addressing the underlying mechanisms of the panic/smoking 
link. The bulk of the literature supports a link between smoking and panic and each 
appeared to have the capacity to serve as a causal factor in the development of 
the other. The pathogenetic explanations of this co-occurrence referred mainly to 3 
hypotheses; neuroticism links smoking to panic as it moderates smoking frequency in 
subjects with a lifetime history of panic (‘the moderational model’), smoking acts as 
a vulnerability factor that modifies the expression of panic disorder by exacerbating 
affective disturbances and negative health processes (’the pathoplastic model of 
dysfunction’), smoking, by means of increasing the risk of lung disease or impacting 
the carotid body, may reduce the threshold to suffocation signals and indirectly 
increase the risk of panic (‘the false suffocation alarm theory’). The first 2 hypotheses 
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have been supported by several studies. A few studies found a unidirectional 
relationship going from smoking to panic, whereas only one study showed a 
bidirectional relationship between smoking and panic. In studies evaluating patients 
with nicotine dependence, it was found that the more severe the level of nicotine 
dependence, the higher the risk of comorbidity with panic. In experimental studies 
almost all studies have found that cigarette-smoking increases fear reactivity to a 
biological challenge, both in panic disorder patients as in healthy volunteers. The 
overall conclusion is that panic and cigarette smoking each appear to have the 
capacity to serve as a causal factor/facilitator in the development of the other. 
Although the temporal pattern and the pathogenetic explanations of such a co-
occurrence are still a matter of debate, cigarette smoking tends to precede the 
onset of panic and to promote panic itself. 
  
In chapter 5, chapter 6 and chapter 7, CBT were used as a behavioral technique to 
gain insight in factors that determine the effect of therapy in PD. In chapter 5 the 
efficacy of an intensive 1-week behavioral therapy program focusing on 
agoraphobia for PDA patients was examined. The outcomes on the agoraphobia 
score of the Fear Questionnaire (FQA), FQA as the main outcome measure, were 
compared after a 1-week intensive therapy (96 patients) and a twice-weekly 
therapy (98 patients). Agoraphobia was found to improve significantly in both 
groups, 1 week and 3 months after therapy, respectively. These findings suggest that 
behavioral therapy for agoraphobia can be shortened if intensified without 
affecting therapy outcome. 
  
In chapter 6, the results of a study in a large group of outpatients examining the 
relationship of comorbid depression on treatment outcome for manualized 
behavioral therapy for PDA, are described. In line with most recent studies, the study 
shows that both depressed and non-depressed PDA patients profit from CBT 
focused on the PDA. Both groups improved significantly during therapy with a 
reduction of more than 70% on initial scores on the PAS and a reduction of more 
than 67% on initial scores on the FQA. In the depressed group the FQA score was 
reduced from severe agoraphobia at baseline to agoraphobia in remission at post-
treatment and in the non-depressed group from severe agoraphobia at baseline to 
agoraphobia in remission at post-treatment. Although the comorbidity group had 
significantly higher scores on the anxiety scales (PAS, FQA) at baseline, there were 
no significant differences at post-treatment between groups. Also in line with 
previous studies, the present study confirmed that manualized behavioral treatment 
focusing on PDA also effectively reduces depressive symptomatology as measured 
by the MADRS. There was a significant effect of treatment on the depressive 
symptoms in both groups, although the depressed PDA patients still scored 
significantly higher at post-treatment on the MADRS than did the non-depressed 
PDA patients Together, these data suggest that comorbid depressive disorder is not 
a ‘drawback’ to treatment response and successful treatment of panic disorder is 
associated with reductions of comorbid depressive symptoms. 
  
In chapter 7, genetic techniques were used to explore key neurotransmitter systems 
and surveyed PD patients on their symptom severity. In this study, 99 patients with 
PDA underwent a 1-week in-vivo exposure-based behavior therapy program and 
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were classified according to their 5- HTTLPR genotype. It was found that the LL-
genotype had smaller FQA reductions when compared with patients with the SS-
genotype and the SL-genotype and smaller PAS reductions when compared with 
the SL-genotype. 
Since there was a significant treatment by genotype interaction effect, the results 
show a relationship between the 5-HTT-linked polymorphic region (5-HTTLPR) 
genotype and the response to exposure-based behavior therapy in patients with 
PDA. These findings reveal that the efficacy of exposure-based behavior therapy is 
related to 5-HTTLPR polymorphism where PDA patients with the SS/SL-genotype show 
a larger response when compared to patients with the LL genotype. This study 
suggests a genetic factor in treatment outcome following behavior therapy and 
implicates the serotonergic system in response to CBT in PDA. 
 
In the general discussion in chapter 8 the results of the studies in this thesis are 
discussed with regard for the environmental and genetic factors that influence 
panic and CBT and the clinical relevance of the results. Also, some concluding 
remarks for future research are made.  
 
In chapter 9 (‘Valorization’) the social and economic relevance, the target groups 
to whom (and why) the results are of interest, the activities/ products and the 
innovative nature of the studies performed, are described. 
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SAMENVATTING  
 
De introductie in hoofdstuk 1 beschrijft het dagelijks leven van een patiënt met een 
paniekstoornis. De casus bevat de klinische presentatie, de diagnostische en 
psychometrische evaluatie, het gebruik van de CO2 challenge en de behande-
ling. Ook worden diagnostische handvatten, factoren die een invloed hebben op 
de paniekstoornis en de verschillende mogelijkheden van behandeling van een 
paniekstoornis beschreven.  
 
Hoofdstuk 2 geeft een algemeen overzicht van de studies die werden uitgevoerd in 
kader van dit proefschrift. Het doel van het proefschrift was om de impact van 
genetische en omgevingsfactoren op de paniekstoornis te bevestigen en verklaren. 
Een ander streven was om de kennis over de factoren die een invloed hebben op 
cognitieve gedragstherapie in de behandeling van de paniekstoornis uit te breiden.  
 
Om meer inzicht te krijgen in de omgevingsfactoren die paniek beïnvloeden, 
werden CO2 inhalaties gebruikt als een model om paniek op te wekken en roken 
als een techniek om de paniekreactie te vergroten. In hoofdstuk 3 wordt een 
experimentele studie beschreven die het ‘paniekeffect’ van roken op de CO2 
challenge onderzoekt. Hoewel in beide groepen de basismetingen gelijk waren, 
reageerden de 46 rokers met een paniekstoornis met meer paniek-symptomen op 
de challenge dan de 46 niet-rokers met een paniekstoornis. De vrees- scores 
toonden hetzelfde effect maar dit verschil was niet statistisch significant. Deze 
resultaten suggereren dat roken het 35% CO2 acute ‘paniekeffect’ faciliteert bij 
patiënten met een paniekstoornis en ondersteunt de hypothese dat voorafgaand 
regelmatig roken het risico op een paniekaanval doet toenemen bij patiënten met 
een paniekstoornis.  
  
De literatuur betreffende de comorbiditeit tussen sigaretten roken/ nicotine 
afhankelijkheid en paniek (paniekaanvallen of paniekstoornis met of zonder 
agorafobie) werd besproken in hoofdstuk 4. De opzet van de review was om een 
beter zicht te krijgen op de relatie tussen paniek en roken enerzijds en de mogelijk 
onderliggende etiologische mechanismen anderzijds. De studies die geïncludeerd 
werden, werden verdeeld in 3 categorieën: de studies die een schatting maakten 
van de prevalentie van de gelijktijdige aanwezigheid (‘co- occurrence’) van roken 
/ nicotine afhankelijkheid en paniekaanvallen/ paniekstoornis (met of zonder 
agorafobie), de studies die de 3 causale modellen onderzochten (van paniek naar 
roken, van roken naar paniek, en gedeelde kwetsbaarheid) en tenslotte de 
experimentele studies. Bij deze laatste werd gebruik gemaakt van procedures die 
een paniek-reactie kunnen opwekken in een laboratorium om zo de onderliggende 
mechanismen van het verband tussen paniek en roken te achterhalen. Het grootste 
deel van de literatuur ondersteunt een link tussen roken en paniek waarbij beide het 
vermogen lijken te hebben om als causale factor te kunnen dienen in de 
ontwikkeling van de andere. De pathogenetische verklaringen van deze ‘co-
occurrence’ refereren hoofdzakelijk naar 3 hypotheses. Neuroticisme ‘linkt’ roken 
aan paniek omdat het een invloed heeft op de frequentie van roken in patiënten 
met een voorgeschiedenis van paniek (‘the moderational model’). Roken kan ook 
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beschouwd worden als een kwetsbaarheidsfactor die de uiting van de 
paniekstoornis wijzigt door het verergeren van affectieve ontregelingen en 
negatieve gezondheidsprocessen (’the pathoplastic model of dysfunction’). 
Tenslotte kan roken het risico op longaandoeningen vergroten of rechtstreeks een 
invloed uitoefenen op de carotis lichaampjes en zo de drempel voor 
verstikkingssignalen verlagen, waardoor indirect het risico op paniek toeneemt (‘the 
false suffocation alarm theory’). De eerste 2 hypotheses werden onder-steund door 
verschillende onderzoeken. Enkele onderzoeken vonden een unidirectioneel 
verband van roken naar paniek, terwijl maar één onderzoek een bidirectioneel 
verband aantoonde tussen roken en paniek. In onderzoeken die patiënten met een 
nicotine afhankelijkheid onderzochten, werd aangetoond dat hoe groter de 
afhankelijkheid van nicotine is, hoe hoger het risico is op comorbiditeit met paniek. 
In experimentele onderzoeken hebben bijna alle studies aangetoond dat roken de 
‘vrees reactiviteit’ doet toenemen als reactie op een biologische challenge en dit 
zowel in patiënten met een paniekstoornis als in gezonde vrijwilligers. De algemene 
conclusie is dat paniek en sigaretten roken elk het vermogen lijken te hebben om te 
dienen als causale factor / facilitator in de ontwikkeling van de andere. Hoewel het 
tijdsverloop en de pathogenetische verklaringen van een dergelijke ‘co-
occurrence’ nog steeds het voorwerp van discussie zijn, lijkt het dat roken het begin 
van de paniekstoornis vooraf gaat en paniek zelf bevordert. 
  
In hoofdstuk 5, hoofdstuk 6 en hoofdstuk 7, werd cognitieve gedragstherapie (CGT) 
gebruikt als een techniek om inzicht te krijgen in de factoren die het effect van 
therapie bepalen bij de paniekstoornis. In hoofdstuk 5 werd onderzocht hoe 
effectief CGT, gericht op agorafobie, is als CGT als een intensief (‘1- week’) 
programma wordt gegeven bij patiënten met een paniekstoornis. De uitkomsten 
van de agorafobie score van de Fear Questionnaire (FQA) als de belangrijkste 
uitkomstmaat werden vergeleken na een 1 week intensief programma (98 
patiënten) versus een twee- wekelijkse therapie (98 patiënten). De mate van 
agorafobie nam significant af in beide groepen en dit respectievelijk 1 week en 3 
maanden na therapie. Deze bevindingen suggereren dat de duur van het geven 
van gedragstherapie gericht op agorafobie korter kan indien de therapie 
intensiever wordt gegeven en dit zonder het resultaat van de behandeling te 
beïnvloeden.  
 
In hoofdstuk 6 worden de resultaten beschreven van een onderzoek in een grote 
groep ambulante patiënten waarin de relatie van een comorbide depressieve 
stoornis op de behandeluitkomst van gedragstherapie voor paniekstoornis wordt 
onderzocht. In overeenstemming met de meest recente studies, toont dit onderzoek 
aan dat zowel depressieve als niet- depressieve patiënten met een paniekstoornis 
met agorafobie baat hebben van CGT die gericht is op de paniekstoornis met 
agorafobie. Beide groepen verbeterden significant tijdens therapie met een 
afname van meer dan 70% van de PAS –scores en een afname van meer dan 67% 
van de FQA- scores ten opzichte van de scores bij het begin van de behandeling. 
De FQA- scores in de depressieve groep namen af van ernstige agorafobie bij start 
van de behandeling naar agorafobie in remissie na de behandeling. De FQA-scores 
in de niet-depressieve groep namen af van ernstige agorafobie bij start van de 
behandeling naar agorafobie in remissie na de behandeling.  
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Hoewel de depressieve groep bij start van de behandeling significant hogere scores 
had op de angst- schalen (PAS, FQA), waren er na de behandeling geen 
significante verschillen tussen de 2 groepen. In overeenstemming met eerdere 
studies, bevestigt dit onderzoek dat op behandelrichtlijnen gebaseerde 
gedragstherapie gericht op de paniekstoornis met agorafobie ook doeltreffend de 
depressieve symptomen reduceert. Er was een significant effect van behandeling 
op de depressieve symptomen in beide groepen hoewel de depressieve patiënten 
na de behandeling wel nog steeds significant hoger scoorden op de MADRS dan 
de niet – depressieve patiënten. Deze data geven aan dat een comorbide 
depressieve stoornis geen nadeel is voor de behandeluitkomst en dat succesvolle 
behandeling van de paniekstoornis geassocieerd is met een afname van de 
comorbide depressieve symptomen.  
  
In hoofdstuk 7 werden genetische technieken gebruikt om fundamentele 
neurotransmittor systemen te onderzoeken en de ernst van de symptomen van 
patiënten met een paniekstoornis na te gaan. In dit onderzoek volgden 99 
patiënten met een paniekstoornis met agorafobie een 1-week in-vivo exposure-
gericht CGT programma en werden de patiënten geclassificeerd volgens hun 5- 
HTTLPR genotype. Het onderzoek toonde aan dat patiënten met het LL-genotype 
een kleinere afname hadden van de FQA- en PAS- scores in vergelijking met de 
patiënten met het SS- en het SL-genotype. Gezien er een significant ‘treatment x 
genotype interaction’ effect was, tonen de resultaten een verband tussen het 5-
HTT-linked polymorphic region (5-HTTLPR) genotype en het effect van de exposure- 
gerichte gedragstherapie in patiënten met een paniekstoornis met agorafobie. 
Deze bevindingen onthullen dat het effect van exposure- gerichte gedragstherapie 
verbonden is aan het 5-HTTLPR polymorfisme en dat patiënten met een 
paniekstoornis met agorafobie die het SS/SL-genotype hebben een groter effect 
ondervinden van therapie in vergelijking met patiënten met het LL genotype. Dit 
onderzoek suggereert dat een genetische factor een invloed heeft op de uitkomst 
van gedragstherapie en impliceert dat het serotonerge systeem een rol speelt in de 
CGT bij patiënten met een paniekstoornis met agorafobie.  
 
In de algemene discussie in hoofdstuk 8 worden de resultaten van het onderzoek in 
dit proefschrift besproken met aandacht voor de omgevings- en genetische 
factoren die paniek en CGT beïnvloeden en het klinische belang van de resultaten. 
Ook worden er enkele afsluitende voorstellen gedaan voor toekomstig onderzoek.  
 
In hoofdstuk 9 (‘Valorization’) wordt het sociale en economische belang, de 
doelgroepen voor wie de resultaten van de gedane onderzoeken van belang zijn 
(en waarom), de activiteiten/ produkten en het innovatieve van de onderzoeken 
beschreven.  
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DANK  
 
Aan het einde van een proefschrift hoor je een aantal mensen te bedanken;  
prof. dr. Eric Griez die mij de kans heeft gegeven met dit proefschrift te starten, prof. 
dr. Inez Myin-Germeys om de taak van prof. dr. Eric Griez op het einde van dit 
promotietraject over te nemen, dr. Koen Schruers om mij de kans te geven dit 
proefschrift te schrijven en mij erbij te begeleiden.  
 
Een speciale dank aan al de patiënten die ondanks hun klachten bereid waren om 
DNA af te staan in kader van dit proefschrift.  
 
In september 2007 ben ik aan dit proefschrift begonnen. De combinatie van maar 6 
uren academisering per week, een fulltimebaan (patiëntenzorg, management, 
onderwijstaken), een aanvullende master opleiding (master in affective 
neuroscience) en een gezin met 2 heel kleine kinderen, hebben er voor gezorgd 
dat het afronden van dit proefschrift uiteindelijk een grote ‘to do’ werd. Maar het 
proefschrift is nu af! 
 
De eerste 4 jaren heb ik vele lange avonden doorgebracht in Vijverdal om 
informatie te verzamelen voor de database.  
Het zoeken naar de best bruikbare DNA- kit (welke vorm kan door een brieven-bus, 
wat moet in de brief staan die we meesturen naar de patiënt?), het zoeken naar 
briefomslagen, het zoeken naar patiënten die werden behandeld voor een 
paniekstoornis (zoals stapels oude facturen doornemen… Rudy dank je om deze 
gedurende jaren te bewaren!), het zoeken in patiëntendossiers naar de nodige 
informatie (zowel in de oude papieren dossiers als in de 4 (of meer?) EPD’s die 
gepasseerd zijn de afgelopen jaren in de Mondriaan en allemaal onoverzichtelijk 
waren en zijn…), het zoeken naar klinimetriescores in de oude dossiers in de kelder 
van Vijverdal (maar waar wateroverlast veel dossiers heeft beschadigd…. doch 
Nicolette soms nog wat kon terugvinden…. Nicolette dank je!) waren ook 
werkzaamheden die de eerste jaren heel veel tijd vergden. 
 
Wegens het ontbreken van een vaste onderzoeksassistent(e) waren de studenten 
die ik begeleid heb met hun ‘WESP- stage’ van onschatbare waarde: veel dank 
Mieke Bareman, Len Hamers, Maddy Duizings en Sara Smeets om de patiënten te 
contacteren met de vraag of ze DNA wouden afstaan.  
Lies en Marlies, de ‘angst- onderzoekers’: Lies, dank voor het snoepgoed dat je wel 
altijd ergens had liggen (..) en bedankt dat ik je kamer gedurende een tijdje mocht 
delen. Nu het onderzoek is afgerond, zal afspreken veel makkelijker gaan! Marlies, 
dank voor je goede raad bij het opstarten van de database. 
Ine en Jolanda, dank om een antwoord te hebben op mijn vele praktische vragen.  
Ron, dank voor je ondersteuning als ik voor de zoveelste keer ‘computer- troubles’ 
had!  
Thea, je minutieuze stijl van de artikels door te nemen en te voorzien van kritische, 
maar altijd opbouwende, commentaar heb ik heel erg gewaardeerd. Ook dank 
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dat je er altijd was als ik een luisterend oor nodig had. Je integriteit zal mij bij blijven. 
Fijn dat je mijn paranimf wou zijn. Ik ga je missen als collega maar ik hoop dat we 
contact houden! 
Gunther (Kenis), ik ben mij altijd blijven verbazen over de grote discrepantie tussen 
jouw bescheidenheid en je grote kennis. Het was fijn een ‘echte Vlaming’ in de 
buurt te hebben! Ook dank voor de fijne gesprekken over het leven en onze 
zoektocht naar wat echt belangrijk is. De laatste jaren hadden we nog maar weinig 
contact doch die gesprekken blijven in mijn herinnering. Dank! 
Leni Noteborn, dank voor je aangename aanwezigheid als ik in Vijverdal aan het 
werk was. Ik heb je oprechte belangstelling voor mijn dochtertjes altijd erg 
gewaardeerd! 
 
Als je onderzoek combineert met veel andere werkzaamheden, spelen deze 
werkzaamheden (en de collega’s aldaar) een belangrijke rol in het verloop (of de 
stagnatie) van het onderzoek. 
Uit angst sommige collega’s uit de patiëntenzorg te vergeten, ga ik geen namen 
noemen, maar veel dank aan de fijne collega’s met wie ik de afgelopen jaren heb 
samengewerkt; secretaresses, psychiaters, psychologen, verpleegkundigen, 
logopedisten, ergotherapeuten, cognitief trainers, klinimetristen, psychologisch 
assistenten, stagiaires... In de afgelopen jaren ben ik betrokken geweest bij de 
oprichting van de afdeling NAH, de poli NAH, poli ADHD en poli ASS en telkens had 
ik het voorrecht om samen te mogen werken met enthousiaste en bekwame 
mensen. Ik heb veel van jullie allemaal geleerd en zal nog vaak met plezier aan 
jullie terugdenken in mijn verdere loopbaan; dank! 
Een paar mensen wil ik echter toch graag noemen. 
Lieve Femie, jouw vriendschap en steun de afgelopen 11 jaren waren voor mij van 
onschatbare waarde. Je was er altijd om de mooie maar ook om de moeilijke 
momenten te delen. Ook dank voor de ‘lay-out’ van dit proefschrift. Mijn vertrek uit 
Maastricht betekent zeker niet het einde van onze vriendschap!  
Rudolf, dank dat je mij 11 jaren geleden de kans hebt gegeven om naar Maastricht 
te komen. De jaren op de ‘NAH’ waren turbulent te noemen (financiële perikelen 
maakte veel plannen niet realiseerbaar) maar waren ook fantastische jaren waarin 
ik veel heb geleerd en waaraan ik met heel veel plezier aan terug denk! 
Ook dank aan de vele secretariaten die de nodige ondersteuning boden (Ineke, 
dank om rekening te houden met mijn drukke agenda als je de diensten moest 
plannen; ik heb het heel erg gewaardeerd!). 
 
Naast patiëntenzorg en wetenschappelijk onderzoek, heb ik de afgelopen jaren 
ook managmenttaken in de Mondriaan en onderwijstaken aan de universiteit 
Maastricht gehad.  
Dank aan de vele collega’s waarmeer ik heb samengewerkt In kader van mijn 
managementstaken. 
Een speciale dank aan Marlie en Nicolle om alles in goede banen te leiden. Petra, 
dank je voor je daadkracht en gedrevenheid; het was erg fijn om met je samen te 
werken! 
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Irene, dank om mij in 2011 de kans te geven om manager zorg te worden. Ik 
herinner mij nog uw woorden ‘iedereen moet ooit de kans krijgen om te beginnen’. 
Dank om mij de afgelopen jaren bij te staan met raad en daad; ik heb dat heel erg 
gewaardeerd!  
Jos van Lier, mijn collega manager … Dank voor de fantastische samenwerking de 
afgelopen jaren. Ik heb zoveel van je geleerd. Ik heb je leren kennen als een 
integer, eerlijk, betrouwbaar en heel aangenaam persoon voor wie de zorg voor de 
patiënt altijd centraal staat. Ik ga onze samenwerking heel hard missen maar we 
houden contact! 
 
Ook dank aan de collega’s die ik heb ontmoet tijdens de onderwijstaken met een 
speciale dank aan een paar collega’s. 
Inge (Crolla), dank je om de onderwijstaken goed te organiseren (en rekening te 
houden met mijn drukke agenda) en je interesse in mijn dochtertjes.  
Rob (van Diest), het woord dat jou het best omschrijft is ‘authentiek’ en dat heb ik 
altijd bijzonder gewaardeerd. Dank voor je eerlijkheid, vriendschap en steun! We 
houden contact! 
Maarten (Bak), samenwerken met jou was altijd aangenaam en zeker nooit saai. 
Het maken van de video ‘het psychiatrisch onderzoek’ voor de studenten was een 
belevenis die in mijn geheugen gegrift staat. Dank! 
 
Bij het afronden van dit proefschrift wat tevens ook het einde betekent van mijn tijd 
bij de Mondriaan, blik ik ook even verder terug naar de tijd waarin mijn interesse 
voor wetenschappelijk onderzoek werd gewekt. In het bijzonder denk ik dan aan de 
collega’s van het AZ- VUB (Vrije Universiteit Brussel) waar ik de eerste jaren van mijn 
opleiding tot psychiater heb gewerkt. Deze jaren waren de zwaarste maar 
gelijktijdig ook de mooiste. Ilse (Coulier) en Chris (Baeken), dank voor de mooie 
herinneringen! Als ik een definitie moet geven van wat collegialiteit is, denk ik aan 
jullie! Ilse, we hebben de laatste jaren minder contact gehad, maar je bent er als ik 
je nodig heb (en Andy ook!). Bedankt om mijn paranimf te willen zijn.  
Dank ook aan de andere collega’s van ‘de VUB’ (hoofdverpleegkundige, ver-
pleegkundigen, ergotherapeute etc) met wie ik heel graag heb samengewerkt. De 
ochtendoverleggen liepen vaak uit omdat het zo gezellig was want ook de laatste 
fims, theaterstukken of ‘persoonlijke belevenissen’ kregen de nodige aandacht 
…het overleg structureren was voor de hoofdverpleegkundige dan ook niet de 
makkelijkste taak… Ook postuum heel veel dank aan prof. dr. Hugo D’Haenen die 
mij inspireerde en stimuleerde om het altijd beter te willen doen. Prof. D’Haenen wist 
mijn interesse te prikkelen voor zowel patiëntenzorg als wetenschappelijk onderzoek 
en leerde mij wat een mooi ‘vak’ psychiater zijn is. Niet alleen als psychiater en als 
wetenschapper maar ook als mens, heb ik hem altijd hoog geacht.  
Ook een speciale dank aan prof. dr. F. Verhey van wie ik veel geleerd heb tijdens 
mijn 4de jaar in opleiding tot psychiater op de geheugenpoli in het azM. Mijn 
interesse in de ‘neuropsychiatrie’ werd daar nog aangewakkerd.  
Prof Verhey, ik heb u altijd gewaardeerd voor uw kennis, betrokkenheid en voor het 
feit dat u mij ‘mijzelf’ liet zijn (‘je mag dr. zeggen als je dat makkelijker vindt dan 
Frans’ of ‘we laten normofoor in de brief staan want dat is ook juist’). Om als 
assistent in opleiding te kunnen groeien moet je voelen dat men in je gelooft. Dank! 
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En de belangrijkste mensen heb ik voor het laatst bewaard … 
Mama en Papa, er zijn geen woorden om uit te drukken hoe dankbaar ik ben voor 
jullie liefde, vertrouwen, hulp en steun tijdens het schrijven van dit proefschrift. Het 
zijn moeilijke jaren geweest op het persoonlijke vlak maar we hebben ook heel veel 
mooie momenten samen gehad. Dank om ons uit de nood te helpen als we geen 
Anna- Laura niet konden gaan halen op school en als we geen opvang hadden 
voor de kindjes, bedankt Papa om in de tuin te komen werken…Mama en Papa, 
bedankt dat jullie er altijd zijn! Zonder jullie was dit proefschrift er nooit gekomen. 
Zussen en broer, jullie zijn er altijd geweest, altijd bereikbaar, altijd steunend en 
goede raad gevend. Jullie vriendschap en liefde betekenen heel veel voor mij; heel 
veel dank! 
Mijn nichtjes en neefjes, Sterre, Erinn, Minne, Wies en Bram: jullie hebben mijn leven 
zoveel ‘plezanter’ en waardevoller gemaakt. Dank voor de vele gezellige 
momenten! 
 
Gabriel, wij hebben de afgelopen jaren een lange weg afgelegd en het was niet 
altijd de makkelijkste weg maar het resultaat mag er wel zijn! 
Dank voor je liefde, vriendschap, vertrouwen en steun.  
 
Anna-Laura en Ella-Julie, mijn grootste ‘verwezenlijkingen’! Het leven werd niet 
rustiger maar is zoveel mooier geworden nu jullie er zijn. Ik hou ontzettend veel van 
jullie! Anna–Laura, de vele ochtenden dat we om 7:00 de trap afgingen en je met 
dat kleine stemmetje zei ‘het is wel nog donker he mama’, zijn verleden tijd.  
Nu het proefschrift af is, en mama terug ‘naar huis’ komt, gaan we veel meer tijd 
samen hebben! Ixtapa, we komen eraan! 
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‘Every new beginning comes from some other beginning’s end’ (Seneca) 
 
